{"data_date":"2026-11-08","library_size":29380,"matched_against":"each record's title and abstract (summary field), case-insensitive","n":342,"page":"https://alzhub.org/answers/semaglutide-glp1-dementia","query":"title or abstract mentions \"semaglutide\", \"liraglutide\", \"dulaglutide\", \"exenatide\", \"tirzepatide\", \"GLP-1\", \"glucagon-like peptide\" or a brand name (Ozempic, Wegovy, Mounjaro)","studies":[{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-oral-semaglutide-14-mg-flexible-dose-in-early-c800c391","doi":null,"journal":"The Lancet","n_participants":3808,"pmid":null,"source_url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00459-9/fulltext","study_design":"phase-3-trial","title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials","title_match":true,"year":2026},{"alzhub_score":68,"alzhub_url":"https://alzhub.org/study/associations-of-semaglutide-with-first-time-diagnosis-of-alzheimer-s-228e687c","doi":null,"journal":"Alzheimer's & Dementia","n_participants":1090000,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11667504/","study_design":"cohort","title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","title_match":true,"year":2024},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/liraglutide-in-mild-to-moderate-alzheimer-s-disease-a-phase-2b-41326666","doi":"10.1038/s41591-025-04106-7","journal":"Nature Medicine","n_participants":204,"pmid":"41326666","source_url":"https://pubmed.ncbi.nlm.nih.gov/41326666/","study_design":"phase-2-trial","title":"Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial","title_match":true,"year":2025},{"alzhub_score":65,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-and-incidence-of-dementia-40690769","doi":"10.7326/ANNALS-24-02648","journal":"Annals of Internal Medicine","n_participants":7254,"pmid":"40690769","source_url":"https://pubmed.ncbi.nlm.nih.gov/40690769/","study_design":"cohort","title":"Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes: A Target Trial Emulation","title_match":true,"year":2025},{"alzhub_score":58,"alzhub_url":"https://alzhub.org/study/comparative-dementia-risk-with-glp1-receptor-agonists-sglt2-41420258","doi":"10.1186/s13195-025-01929-x","journal":"Alzheimer's Research & Therapy","n_participants":107424,"pmid":"41420258","source_url":"https://pubmed.ncbi.nlm.nih.gov/41420258/","study_design":"cohort","title":"Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","title_match":true,"year":2025},{"alzhub_score":65,"alzhub_url":"https://alzhub.org/study/anti-diabetic-agents-and-the-risks-of-dementia-in-patients-with-type-39716328","doi":"10.1186/s13195-024-01645-y","journal":"Alzheimer's Research & Therapy","n_participants":3462926,"pmid":"39716328","source_url":"https://pubmed.ncbi.nlm.nih.gov/39716328/","study_design":"meta-analysis","title":"Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/a-novel-dual-glp-1-gip-receptor-agonist-alleviates-cognitive-decline-28342971","doi":"10.1016/j.bbr.2017.03.032","journal":"Behavioural brain research","n_participants":null,"pmid":"28342971","source_url":"https://pubmed.ncbi.nlm.nih.gov/28342971/","study_design":null,"title":"A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","title_match":true,"year":2017},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/pharmacologically-reversible-zonation-dependent-endothelial-cell-32887883","doi":"10.1038/s41467-020-18249-3","journal":"Nature communications","n_participants":null,"pmid":"32887883","source_url":"https://pubmed.ncbi.nlm.nih.gov/32887883/","study_design":null,"title":"Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain","title_match":false,"year":2020},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/mexico-city-normal-weight-children-exposed-to-high-concentrations-of-26037109","doi":"10.1016/j.envres.2015.05.012","journal":"Environmental research","n_participants":null,"pmid":"26037109","source_url":"https://pubmed.ncbi.nlm.nih.gov/26037109/","study_design":null,"title":"Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease","title_match":false,"year":2015},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/cardioprotective-glucose-lowering-agents-and-dementia-risk-a-40193122","doi":"10.1001/jamaneurol.2025.0360","journal":"JAMA neurology","n_participants":164,"pmid":"40193122","source_url":"https://pubmed.ncbi.nlm.nih.gov/40193122/","study_design":"meta-analysis","title":"Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis","title_match":false,"year":2025},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/effects-of-liraglutide-on-neurodegeneration-blood-flow-and-cognition-23158895","doi":null,"journal":"Danish medical journal","n_participants":20,"pmid":"23158895","source_url":"https://pubmed.ncbi.nlm.nih.gov/23158895/","study_design":null,"title":"Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer\u00b4s disease - protocol for a controlled, randomized double-blinded trial","title_match":true,"year":2012},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/val8-glucagon-like-peptide-1-prevents-tau-hyperphosphorylation-22115895","doi":"10.1016/j.ejphar.2011.11.005","journal":"European journal of pharmacology","n_participants":null,"pmid":"22115895","source_url":"https://pubmed.ncbi.nlm.nih.gov/22115895/","study_design":null,"title":"(Val\u2078) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains","title_match":true,"year":2012},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/geniposide-ameliorates-learning-memory-deficits-reduces-tau-24329968","doi":"10.1111/bpa.12116","journal":"Brain pathology (Zurich, Switzerland)","n_participants":null,"pmid":"24329968","source_url":"https://pubmed.ncbi.nlm.nih.gov/24329968/","study_design":null,"title":"Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3\u03b2 pathway in streptozotocin-induced alzheimer rat model","title_match":false,"year":2014},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/amelioration-of-neurodegenerative-changes-in-cellular-and-rat-models-21901364","doi":"10.1007/s11357-011-9303-8","journal":"Age (Dordrecht, Netherlands)","n_participants":null,"pmid":"21901364","source_url":"https://pubmed.ncbi.nlm.nih.gov/21901364/","study_design":null,"title":"Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4","title_match":false,"year":2012},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/exendin-4-a-glucagon-like-peptide-1-receptor-agonist-reduces-25479064","doi":"10.1097/jim.0000000000000129","journal":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","n_participants":null,"pmid":"25479064","source_url":"https://pubmed.ncbi.nlm.nih.gov/25479064/","study_design":null,"title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes","title_match":true,"year":2015},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-class-drugs-show-clear-protective-effects-in-38677445","doi":"10.1016/j.neuropharm.2024.109952","journal":"Neuropharmacology","n_participants":null,"pmid":"38677445","source_url":"https://pubmed.ncbi.nlm.nih.gov/38677445/","study_design":null,"title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/potential-new-therapeutic-implications-of-semaglutide-new-colours-of-37950798","doi":"10.1007/s13300-023-01506-1","journal":"Diabetes therapy : research, treatment and education of diabetes and related disorders","n_participants":null,"pmid":"37950798","source_url":"https://pubmed.ncbi.nlm.nih.gov/37950798/","study_design":null,"title":"Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?","title_match":true,"year":2024},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/education-and-alzheimer-disease-genetic-risk-in-associations-of-glp-1-dbbc063a","doi":"10.64898/2026.09.04.26362304","journal":"medRxiv","n_participants":14364,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.04.26362304","study_design":"cohort study","title":"Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes","title_match":true,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/semaglutide-for-obesity-management-a-narrative-review-of-efficacy-42025961","doi":"10.1016/j.japh.2026.103117","journal":"Journal of the American Pharmacists Association : JAPhA","n_participants":null,"pmid":"42025961","source_url":"https://pubmed.ncbi.nlm.nih.gov/42025961/","study_design":"narrative review","title":"Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions","title_match":true,"year":2026},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/interaction-of-glucagon-like-peptide-1-and-its-analogues-with-amyloid-50e87e79","doi":"10.20944/preprints202504.2038.v1","journal":"International journal of molecular sciences","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202504.2038.v1","study_design":null,"title":"Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-\u03b2 Peptide Affects Its Fibrillation and Cytotoxicity","title_match":true,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/the-diabetes-drug-liraglutide-prevents-degenerative-processes-in-a-21525299","doi":"10.1523/jneurosci.0529-11.2011","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","n_participants":null,"pmid":"21525299","source_url":"https://pubmed.ncbi.nlm.nih.gov/21525299/","study_design":null,"title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","title_match":true,"year":2011},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-a-focus-on-neurodegenerative-diseases-31680842","doi":"10.3389/fnins.2019.01112","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"31680842","source_url":"https://pubmed.ncbi.nlm.nih.gov/31680842/","study_design":null,"title":"Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases","title_match":true,"year":2019},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-2f85dd17","doi":"10.18103/mra.v14i1.7163","journal":"Medical Research Archives","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.18103/mra.v14i1.7163","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-eb95fab7","doi":"10.5281/zenodo.18531026","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18531026","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-11d677d7","doi":"10.5281/zenodo.18531027","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18531027","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2026},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/tirzepatide-compared-with-semaglutide-and-10-year-cardiovascular-40980721","doi":"10.1093/ehjopen/oeaf117","journal":"European Heart Journal Open","n_participants":null,"pmid":"40980721","source_url":"https://pubmed.ncbi.nlm.nih.gov/40980721/","study_design":"randomized controlled trial","title":"Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial","title_match":true,"year":2025},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/the-integration-of-lifestyle-modification-advice-and-diet-and-41252315","doi":"10.1159/000548370","journal":"Obesity Facts","n_participants":null,"pmid":"41252315","source_url":"https://pubmed.ncbi.nlm.nih.gov/41252315/","study_design":"meta-analysis","title":"The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics","title_match":false,"year":2025},{"alzhub_score":58,"alzhub_url":"https://alzhub.org/study/obesity-and-cancer-mechanisms-epidemiological-evidence-and-potential-41506747","doi":"10.7570/jomes25088","journal":"Journal of Obesity & Metabolic Syndrome","n_participants":null,"pmid":"41506747","source_url":"https://pubmed.ncbi.nlm.nih.gov/41506747/","study_design":"meta-analysis","title":"Obesity and Cancer: Mechanisms, Epidemiological Evidence, and Potential Risk Reduction","title_match":false,"year":2026},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/cardiovascular-risk-reduction-in-metabolic-dysfunction-associated-39826021","doi":"10.1007/s11886-024-02185-5","journal":"Current Cardiology Reports","n_participants":null,"pmid":"39826021","source_url":"https://pubmed.ncbi.nlm.nih.gov/39826021/","study_design":null,"title":"Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis","title_match":false,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/impact-of-glucagonlike-peptide1-receptor-agonists-on-the-dementia-40481813","doi":"10.1002/dmrr.70058","journal":"Diabetes/Metabolism Research and Reviews","n_participants":109778,"pmid":"40481813","source_url":"https://pubmed.ncbi.nlm.nih.gov/40481813/","study_design":null,"title":"Impact of Glucagon\u2010Like Peptide\u20101 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population\u2010Based Longitudinal Cohort Study","title_match":false,"year":2025},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/associations-of-semaglutide-with-alzheimer-s-disease-related-40552638","doi":"10.1177/13872877251351329","journal":"Journal of Alzheimer s Disease","n_participants":null,"pmid":"40552638","source_url":"https://pubmed.ncbi.nlm.nih.gov/40552638/","study_design":null,"title":"Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study","title_match":true,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/cognitive-dysfunction-and-dementia-in-type-2-diabetes-mellitus-40810170","doi":"10.1021/acsptsci.5c00086","journal":"ACS Pharmacology & Translational Science","n_participants":null,"pmid":"40810170","source_url":"https://pubmed.ncbi.nlm.nih.gov/40810170/","study_design":null,"title":"Cognitive Dysfunction and Dementia in Type 2 Diabetes Mellitus: Insights into Mechanisms, Models, and Therapeutics","title_match":false,"year":2025},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/neurodegeneration-and-stroke-after-semaglutide-and-tirzepatide-in-40663350","doi":"10.1001/jamanetworkopen.2025.21016","journal":"JAMA Network Open","n_participants":860,"pmid":"40663350","source_url":"https://pubmed.ncbi.nlm.nih.gov/40663350/","study_design":"cohort study","title":"Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity","title_match":true,"year":2025},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/evaluating-glp-1-receptor-agonists-versus-metformin-as-first-line-40695613","doi":"10.1136/bmjdrc-2025-004902","journal":"BMJ Open Diabetes Research & Care","n_participants":null,"pmid":"40695613","source_url":"https://pubmed.ncbi.nlm.nih.gov/40695613/","study_design":"cohort study","title":"Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/pathomechanisms-genetic-insights-and-therapeutics-in-diabetes-41196686","doi":"10.1530/joe-25-0016","journal":"Journal of Endocrinology","n_participants":null,"pmid":"41196686","source_url":"https://pubmed.ncbi.nlm.nih.gov/41196686/","study_design":null,"title":"Pathomechanisms, genetic insights, and therapeutics in diabetes-associated dementia","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/mechanisms-underlying-cognitive-impairment-and-management-strategies-41169480","doi":"10.3389/fendo.2025.1655768","journal":"Frontiers in Endocrinology","n_participants":null,"pmid":"41169480","source_url":"https://pubmed.ncbi.nlm.nih.gov/41169480/","study_design":null,"title":"Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes","title_match":false,"year":2025},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/evaluating-the-effects-of-liraglutide-empagliflozin-and-linagliptin-40840993","doi":"10.1136/bmjopen-2024-095382","journal":"BMJ Open","n_participants":396,"pmid":"40840993","source_url":"https://pubmed.ncbi.nlm.nih.gov/40840993/","study_design":"open-label trial","title":"Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase","title_match":true,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/analogos-do-glp-1-na-doenca-de-alzheimer-potencial-neuroprotetor-alem-a57b2ca0","doi":"10.55905/rdelosv18.n75-128","journal":"DELOS Desarrollo Local Sostenible","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.55905/rdelosv18.n75-128","study_design":null,"title":"An\u00e1logos do glp-1 na doen\u00e7a de alzheimer: potencial neuroprotetor al\u00e9m do controle glic\u00eamico uma revis\u00e3o narrativa","title_match":true,"year":2025},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-reduce-dementia-and-alzheimer-disease-risk-in-41697144","doi":"10.1093/ndt/gfag032","journal":"Nephrology Dialysis Transplantation","n_participants":null,"pmid":"41697144","source_url":"https://pubmed.ncbi.nlm.nih.gov/41697144/","study_design":"cohort study","title":"GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD","title_match":true,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/genetic-insights-into-protective-effects-of-glp-1-receptor-agonists-dd11f0ff","doi":"10.1212/nxg.0000000000200425","journal":"Neurology Genetics","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1212/nxg.0000000000200425","study_design":null,"title":"Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across Ancestries","title_match":true,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-reduce-dementia-and-alzheimer-disease-risk-in-01baa622","doi":"10.1681/asn.2025rdy8v05v","journal":"Journal of the American Society of Nephrology","n_participants":12351,"pmid":null,"source_url":"https://doi.org/10.1681/asn.2025rdy8v05v","study_design":"cohort study","title":"GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX","title_match":true,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/real-world-evidence-of-glp-1-receptor-agonist-in-neurodegenerative-0b097590","doi":"10.17605/osf.io/ng7mu","journal":"Open Science Framework","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.17605/osf.io/ng7mu","study_design":null,"title":"Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies","title_match":true,"year":2026},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-beyond-glycemic-control-clinical-implications-d1c44bbc","doi":"10.55729/2000-9666.1651","journal":"Journal of Community Hospital Internal Medicine Perspectives","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.55729/2000-9666.1651","study_design":"clinical trial","title":"GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders","title_match":true,"year":2026},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/comment-on-associations-of-semaglutide-with-firsttime-diagnosis-of-40356047","doi":"10.1002/alz.70035","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40356047","source_url":"https://pubmed.ncbi.nlm.nih.gov/40356047/","study_design":null,"title":"Comment on \u201cAssociations of semaglutide with first\u2010time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real\u2010world data in the US\u201d","title_match":true,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-42636218","doi":"10.1371/journal.pone.0356138","journal":"PLoS ONE","n_participants":1528885,"pmid":"42636218","source_url":"https://pubmed.ncbi.nlm.nih.gov/42636218/","study_design":"cohort study","title":"Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/glp-1-based-therapies-beyond-diabetes-emerging-clinical-applications-ffbf0b6d","doi":"10.35630/2026/16/iss.4.14","journal":"Archiv Euromedica","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.35630/2026/16/iss.4.14","study_design":"meta-analysis","title":"GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES","title_match":true,"year":2026},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/what-do-sugar-gila-monsters-and-the-therapeutic-dance-have-in-common-1bda82c8","doi":"10.1212/nxg.0000000000200450","journal":"Neurology Genetics","n_participants":74148,"pmid":null,"source_url":"https://doi.org/10.1212/nxg.0000000000200450","study_design":"meta-analysis","title":"What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia?","title_match":false,"year":2026},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-oral-semaglutide-14-mg-flexible-dose-in-early-41865758","doi":"10.1016/s0140-6736(26)00459-9","journal":"The Lancet","n_participants":928,"pmid":"41865758","source_url":"https://pubmed.ncbi.nlm.nih.gov/41865758/","study_design":"clinical trial","title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials","title_match":true,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/combination-of-intranasal-insulin-and-oral-semaglutide-for-cognition-41434629","doi":"10.1002/alz70860_102127","journal":"Alzheimer s & Dementia","n_participants":24,"pmid":"41434629","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726504/","study_design":null,"title":"Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/semaglutide-improves-cognitive-function-and-neuroinflammation-in-app-40151913","doi":"10.1177/13872877251329439","journal":"Journal of Alzheimer s Disease","n_participants":null,"pmid":"40151913","source_url":"https://pubmed.ncbi.nlm.nih.gov/40151913/","study_design":null,"title":"Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-\u03baB pathway","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/unravelling-shared-pathways-linking-metabolic-syndrome-mild-cognitive-40137124","doi":"10.3390/metabo15030159","journal":"Metabolites","n_participants":null,"pmid":"40137124","source_url":"https://pubmed.ncbi.nlm.nih.gov/40137124/","study_design":null,"title":"Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia","title_match":false,"year":2025},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/the-concentration-dependent-protective-effects-by-new-generation-41359407","doi":"10.1177/01410768251395877","journal":"Journal of the Royal Society of Medicine","n_participants":200068,"pmid":"41359407","source_url":"https://pubmed.ncbi.nlm.nih.gov/41359407/","study_design":"meta-analysis","title":"The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-in-delirium-and-encephalopathies-a-1839cdb4","doi":"10.1007/s44337-025-00428-0","journal":"Discover Medicine","n_participants":38,"pmid":null,"source_url":"https://doi.org/10.1007/s44337-025-00428-0","study_design":null,"title":"GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review","title_match":true,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonist-initiation-and-risk-of-3ea6500a","doi":"10.64898/2026.08.21.26361012","journal":"medRxiv (preprint)","n_participants":6328,"pmid":null,"source_url":"https://doi.org/10.64898/2026.08.21.26361012","study_design":null,"title":"Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning","title_match":true,"year":2026},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/r-we-ready-for-reimbursement-a-round-up-of-developments-in-real-world-41987656","doi":"10.57264/cer-2026-0073","journal":"Journal of comparative effectiveness research","n_participants":null,"pmid":"41987656","source_url":"https://pubmed.ncbi.nlm.nih.gov/41987656/","study_design":null,"title":"R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/coverage-and-prior-authorization-policies-for-semaglutide-and-bcf82ce4","doi":"10.1001/jamanetworkopen.2025.29842","journal":"JAMA Network Open","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1001/jamanetworkopen.2025.29842","study_design":"cross-sectional","title":"Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/effect-of-antidiabetic-drugs-in-alzheimer-s-disease-a-systematic-41146261","doi":"10.1186/s13024-025-00894-1","journal":"Molecular neurodegeneration","n_participants":405,"pmid":"41146261","source_url":"https://pubmed.ncbi.nlm.nih.gov/41146261/","study_design":"systematic review","title":"Effect of antidiabetic drugs in Alzheimer\u00b4s disease: a systematic review of preclinical and clinical studies","title_match":false,"year":2025},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/evoke-and-evoke-design-of-two-large-scale-double-blind-placebo-39780249","doi":"10.1186/s13195-024-01666-7","journal":"Alzheimer's research & therapy","n_participants":210,"pmid":"39780249","source_url":"https://pubmed.ncbi.nlm.nih.gov/39780249/","study_design":"clinical trial","title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/mapping-the-effectiveness-and-risks-of-glp-1-receptor-agonists-39833406","doi":"10.1038/s41591-024-03412-w","journal":"Nature medicine","n_participants":215970,"pmid":"39833406","source_url":"https://pubmed.ncbi.nlm.nih.gov/39833406/","study_design":null,"title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","title_match":true,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/neuroprotective-effects-of-a-triple-glp-1-gip-glucagon-receptor-29050859","doi":"10.1016/j.brainres.2017.10.012","journal":"Brain research","n_participants":null,"pmid":"29050859","source_url":"https://pubmed.ncbi.nlm.nih.gov/29050859/","study_design":null,"title":"Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease","title_match":true,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/brain-insulin-resistance-in-alzheimer-s-disease-and-its-potential-24640977","doi":"10.2217/nmt.13.73","journal":"Neurodegenerative disease management","n_participants":null,"pmid":"24640977","source_url":"https://pubmed.ncbi.nlm.nih.gov/24640977/","study_design":null,"title":"Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs","title_match":true,"year":2014},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/diabetes-and-aging-from-treatment-goals-to-pharmacologic-therapy-30833929","doi":"10.3389/fendo.2019.00045","journal":"Frontiers in endocrinology","n_participants":null,"pmid":"30833929","source_url":"https://pubmed.ncbi.nlm.nih.gov/30833929/","study_design":null,"title":"Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy","title_match":false,"year":2019},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-neuroprotective-effects-of-glucagon-like-peptide-1-in-alzheimer-s-36117625","doi":"10.3389/fnins.2022.970925","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"36117625","source_url":"https://pubmed.ncbi.nlm.nih.gov/36117625/","study_design":null,"title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review","title_match":true,"year":2022},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/targeting-immunometabolic-pathways-for-combination-therapy-in-37786483","doi":"10.1002/trc2.12423","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"37786483","source_url":"https://pubmed.ncbi.nlm.nih.gov/37786483/","study_design":null,"title":"Targeting immunometabolic pathways for combination therapy in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/block-of-a1-astrocyte-conversion-by-microglia-is-neuroprotective-in-29892066","doi":"10.1038/s41591-018-0051-5","journal":"Nature medicine","n_participants":null,"pmid":"29892066","source_url":"https://pubmed.ncbi.nlm.nih.gov/29892066/","study_design":null,"title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","title_match":false,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/an-anti-diabetes-agent-protects-the-mouse-brain-from-defective-22476196","doi":"10.1172/jci57256","journal":"The Journal of clinical investigation","n_participants":null,"pmid":"22476196","source_url":"https://pubmed.ncbi.nlm.nih.gov/22476196/","study_design":null,"title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated A\u03b2 oligomers","title_match":false,"year":2012},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/facilitation-of-lin-12-mediated-signalling-by-sel-12-a-caenorhabditis-7566091","doi":"10.1038/377351a0","journal":"Nature","n_participants":null,"pmid":"7566091","source_url":"https://pubmed.ncbi.nlm.nih.gov/7566091/","study_design":null,"title":"Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene","title_match":false,"year":1995},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/drugs-developed-to-treat-diabetes-liraglutide-and-lixisenatide-cross-22443187","doi":"10.1186/1471-2202-13-33","journal":"BMC neuroscience","n_participants":null,"pmid":"22443187","source_url":"https://pubmed.ncbi.nlm.nih.gov/22443187/","study_design":null,"title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","title_match":true,"year":2012},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/in-alzheimer-s-disease-6-month-treatment-with-glp-1-analog-prevents-27252647","doi":"10.3389/fnagi.2016.00108","journal":"Frontiers in aging neuroscience","n_participants":18,"pmid":"27252647","source_url":"https://pubmed.ncbi.nlm.nih.gov/27252647/","study_design":null,"title":"In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial","title_match":true,"year":2016},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-glucagon-like-peptide-1-glp-receptor-as-a-therapeutic-target-in-26851597","doi":"10.1016/j.drudis.2016.01.013","journal":"Drug discovery today","n_participants":null,"pmid":"26851597","source_url":"https://pubmed.ncbi.nlm.nih.gov/26851597/","study_design":"open-label trial","title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","title_match":true,"year":2016},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/protection-and-reversal-of-excitotoxic-neuronal-damage-by-glucagon-12183643","doi":"10.1124/jpet.102.037481","journal":"The Journal of pharmacology and experimental therapeutics","n_participants":null,"pmid":"12183643","source_url":"https://pubmed.ncbi.nlm.nih.gov/12183643/","study_design":null,"title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","title_match":true,"year":2002},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/liraglutide-can-reverse-memory-impairment-synaptic-loss-and-reduce-23973293","doi":"10.1016/j.neuropharm.2013.08.005","journal":"Neuropharmacology","n_participants":null,"pmid":"23973293","source_url":"https://pubmed.ncbi.nlm.nih.gov/23973293/","study_design":null,"title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease","title_match":true,"year":2014},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-glp-1-medicines-for-type-2-diabetes-and-obesity-38843460","doi":"10.2337/dci24-0003","journal":"Diabetes care","n_participants":null,"pmid":"38843460","source_url":"https://pubmed.ncbi.nlm.nih.gov/38843460/","study_design":null,"title":"Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity","title_match":true,"year":2024},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-decreases-endogenous-amyloid-beta-peptide-12749025","doi":"10.1002/jnr.10611","journal":"Journal of neuroscience research","n_participants":null,"pmid":"12749025","source_url":"https://pubmed.ncbi.nlm.nih.gov/12749025/","study_design":null,"title":"Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron","title_match":true,"year":2003},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-stimulation-reduces-amyloid-beta-peptide-accumulation-20308787","doi":"10.3233/jad-2010-1314","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"20308787","source_url":"https://pubmed.ncbi.nlm.nih.gov/20308787/","study_design":null,"title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease","title_match":true,"year":2010},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-glp-1-receptor-agonists-and-neuroinflammation-36372278","doi":"10.1016/j.phrs.2022.106550","journal":"Pharmacological research","n_participants":null,"pmid":"36372278","source_url":"https://pubmed.ncbi.nlm.nih.gov/36372278/","study_design":null,"title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","title_match":true,"year":2022},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/central-effects-of-glp-1-new-opportunities-for-treatments-of-23999914","doi":"10.1530/joe-13-0221","journal":"The Journal of endocrinology","n_participants":null,"pmid":"23999914","source_url":"https://pubmed.ncbi.nlm.nih.gov/23999914/","study_design":null,"title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/a-novel-neurotrophic-property-of-glucagon-like-peptide-1-a-promoter-11861804","doi":"10.1124/jpet.300.3.958","journal":"The Journal of pharmacology and experimental therapeutics","n_participants":null,"pmid":"11861804","source_url":"https://pubmed.ncbi.nlm.nih.gov/11861804/","study_design":null,"title":"A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells","title_match":true,"year":2002},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/motor-and-cognitive-advantages-persist-12-months-after-exenatide-24662192","doi":"10.3233/jpd-140364","journal":"Journal of Parkinson's disease","n_participants":20,"pmid":"24662192","source_url":"https://pubmed.ncbi.nlm.nih.gov/24662192/","study_design":"randomized controlled trial","title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/impairment-of-synaptic-plasticity-and-memory-formation-in-glp-1-19573562","doi":"10.1016/j.bbr.2009.06.035","journal":"Behavioural brain research","n_participants":null,"pmid":"19573562","source_url":"https://pubmed.ncbi.nlm.nih.gov/19573562/","study_design":null,"title":"Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease","title_match":true,"year":2009},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/link-between-type-2-diabetes-and-alzheimer-s-disease-from-25792818","doi":"10.2147/cia.s74042","journal":"Clinical interventions in aging","n_participants":null,"pmid":"25792818","source_url":"https://pubmed.ncbi.nlm.nih.gov/25792818/","study_design":null,"title":"Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment","title_match":false,"year":2015},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/neuroprotective-and-neurotrophic-actions-of-glucagon-like-peptide-1-22519295","doi":"10.1111/j.1476-5381.2012.01971.x","journal":"British journal of pharmacology","n_participants":null,"pmid":"22519295","source_url":"https://pubmed.ncbi.nlm.nih.gov/22519295/","study_design":null,"title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","title_match":true,"year":2012},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/parkinson-s-disease-insulin-resistance-and-novel-agents-of-22344583","doi":"10.1093/brain/aws009","journal":"Brain : a journal of neurology","n_participants":null,"pmid":"22344583","source_url":"https://pubmed.ncbi.nlm.nih.gov/22344583/","study_design":null,"title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","title_match":false,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/neuroprotective-effects-of-lixisenatide-and-liraglutide-in-the-1-26141845","doi":"10.1016/j.neuroscience.2015.06.054","journal":"Neuroscience","n_participants":null,"pmid":"26141845","source_url":"https://pubmed.ncbi.nlm.nih.gov/26141845/","study_design":null,"title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","title_match":true,"year":2015},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-diabetes-drug-liraglutide-reverses-cognitive-impairment-in-mice-29435980","doi":"10.1002/path.5056","journal":"The Journal of pathology","n_participants":null,"pmid":"29435980","source_url":"https://pubmed.ncbi.nlm.nih.gov/29435980/","study_design":null,"title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","title_match":true,"year":2018},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/evaluating-the-effects-of-the-novel-glp-1-analogue-liraglutide-in-30944040","doi":"10.1186/s13063-019-3259-x","journal":"Trials","n_participants":206,"pmid":"30944040","source_url":"https://pubmed.ncbi.nlm.nih.gov/30944040/","study_design":null,"title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)","title_match":true,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/insulin-igf-1-and-glp-1-signaling-in-neurodegenerative-disorders-24582776","doi":"10.1016/j.pneurobio.2014.02.005","journal":"Progress in neurobiology","n_participants":null,"pmid":"24582776","source_url":"https://pubmed.ncbi.nlm.nih.gov/24582776/","study_design":null,"title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/novel-glp-1-mimetics-developed-to-treat-type-2-diabetes-promote-21312223","doi":"10.1002/jnr.22565","journal":"Journal of neuroscience research","n_participants":null,"pmid":"21312223","source_url":"https://pubmed.ncbi.nlm.nih.gov/21312223/","study_design":null,"title":"Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain","title_match":true,"year":2011},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/the-glp-1-receptor-agonist-liraglutide-improves-memory-function-and-25869785","doi":"10.3233/jad-143090","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"25869785","source_url":"https://pubmed.ncbi.nlm.nih.gov/25869785/","study_design":null,"title":"The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease","title_match":true,"year":2015},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/treatment-with-glucagon-like-peptide-1-receptor-agonists-and-35229024","doi":"10.1002/trc2.12268","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":15820,"pmid":"35229024","source_url":"https://pubmed.ncbi.nlm.nih.gov/35229024/","study_design":null,"title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","title_match":true,"year":2022},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/brain-uptake-pharmacokinetics-of-incretin-receptor-agonists-showing-32755557","doi":"10.1016/j.bcp.2020.114187","journal":"Biochemical pharmacology","n_participants":null,"pmid":"32755557","source_url":"https://pubmed.ncbi.nlm.nih.gov/32755557/","study_design":null,"title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","title_match":false,"year":2020},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/potential-role-of-glucagon-like-peptide-1-glp-1-in-neuroprotection-22938097","doi":"10.2165/11635890-000000000-00000","journal":"CNS drugs","n_participants":null,"pmid":"22938097","source_url":"https://pubmed.ncbi.nlm.nih.gov/22938097/","study_design":null,"title":"Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection","title_match":true,"year":2012},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/novel-dual-glp-1-gip-receptor-agonists-show-neuroprotective-effects-29402504","doi":"10.1016/j.neuropharm.2018.01.040","journal":"Neuropharmacology","n_participants":null,"pmid":"29402504","source_url":"https://pubmed.ncbi.nlm.nih.gov/29402504/","study_design":null,"title":"Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","title_match":true,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-analogues-enhance-synaptic-plasticity-in-the-20035739","doi":"10.1016/j.ejphar.2009.12.023","journal":"European journal of pharmacology","n_participants":null,"pmid":"20035739","source_url":"https://pubmed.ncbi.nlm.nih.gov/20035739/","study_design":null,"title":"Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease","title_match":true,"year":2010},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-improves-the-supportive-ability-of-astrocytes-to-neurons-by-33556642","doi":"10.1016/j.molmet.2021.101180","journal":"Molecular metabolism","n_participants":null,"pmid":"33556642","source_url":"https://pubmed.ncbi.nlm.nih.gov/33556642/","study_design":null,"title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/saxagliptin-a-dipeptidyl-peptidase-4-inhibitor-ameliorates-23603201","doi":"10.1016/j.neuropharm.2013.04.008","journal":"Neuropharmacology","n_participants":null,"pmid":"23603201","source_url":"https://pubmed.ncbi.nlm.nih.gov/23603201/","study_design":null,"title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","title_match":false,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lixisenatide-a-drug-developed-to-treat-type-2-diabetes-shows-25107586","doi":"10.1016/j.neuropharm.2014.07.015","journal":"Neuropharmacology","n_participants":null,"pmid":"25107586","source_url":"https://pubmed.ncbi.nlm.nih.gov/25107586/","study_design":null,"title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease","title_match":false,"year":2014},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/antidiabetic-medication-and-risk-of-dementia-in-patients-with-type-2-31437816","doi":"10.1530/eje-19-0259","journal":"European journal of endocrinology","n_participants":250,"pmid":"31437816","source_url":"https://pubmed.ncbi.nlm.nih.gov/31437816/","study_design":"case-control study","title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","title_match":false,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/human-presenilin-1-but-not-familial-alzheimer-s-disease-fad-mutants-9680315","doi":"10.1046/j.1365-4624.1997.00012.x","journal":"Genes and function","n_participants":null,"pmid":"9680315","source_url":"https://pubmed.ncbi.nlm.nih.gov/9680315/","study_design":null,"title":"Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing","title_match":false,"year":1997},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/brain-insulin-resistance-role-in-neurodegenerative-disease-and-32175781","doi":"10.1080/13543784.2020.1738383","journal":"Expert opinion on investigational drugs","n_participants":null,"pmid":"32175781","source_url":"https://pubmed.ncbi.nlm.nih.gov/32175781/","study_design":null,"title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","title_match":false,"year":2020},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/a-pilot-study-of-exenatide-actions-in-alzheimer-s-disease-31518224","doi":"10.2174/1567205016666190913155950","journal":"Current Alzheimer research","n_participants":null,"pmid":"31518224","source_url":"https://pubmed.ncbi.nlm.nih.gov/31518224/","study_design":null,"title":"A Pilot Study of Exenatide Actions in Alzheimer's Disease","title_match":true,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-and-the-central-peripheral-nervous-system-27871675","doi":"10.1016/j.tem.2016.10.001","journal":"Trends in endocrinology and metabolism: TEM","n_participants":null,"pmid":"27871675","source_url":"https://pubmed.ncbi.nlm.nih.gov/27871675/","study_design":null,"title":"Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes","title_match":true,"year":2017},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/blood-brain-glucose-transfer-in-alzheimer-s-disease-effect-of-glp-1-29235507","doi":"10.1038/s41598-017-17718-y","journal":"Scientific reports","n_participants":18,"pmid":"29235507","source_url":"https://pubmed.ncbi.nlm.nih.gov/29235507/","study_design":null,"title":"Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment","title_match":true,"year":2017},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/antidiabetic-agents-as-a-novel-treatment-for-alzheimer-s-and-37328112","doi":"10.1016/j.arr.2023.101979","journal":"Ageing research reviews","n_participants":null,"pmid":"37328112","source_url":"https://pubmed.ncbi.nlm.nih.gov/37328112/","study_design":null,"title":"Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease","title_match":false,"year":2023},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/val-8-glp-1-rescues-synaptic-plasticity-and-reduces-dense-core-20359773","doi":"10.1016/j.neurobiolaging.2010.02.014","journal":"Neurobiology of aging","n_participants":null,"pmid":"20359773","source_url":"https://pubmed.ncbi.nlm.nih.gov/20359773/","study_design":null,"title":"Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice","title_match":true,"year":2012},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-diabetes-drug-liraglutide-ameliorates-aberrant-insulin-receptor-23011726","doi":"10.1007/s12017-012-8199-5","journal":"Neuromolecular medicine","n_participants":null,"pmid":"23011726","source_url":"https://pubmed.ncbi.nlm.nih.gov/23011726/","study_design":null,"title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer's disease","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/long-term-inhibition-of-dipeptidyl-peptidase-4-in-alzheimer-s-prone-20005285","doi":"10.1016/j.exger.2009.12.004","journal":"Experimental gerontology","n_participants":null,"pmid":"20005285","source_url":"https://pubmed.ncbi.nlm.nih.gov/20005285/","study_design":null,"title":"Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice","title_match":false,"year":2010},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glp-1-agonists-facilitate-hippocampal-ltp-and-reverse-the-impairment-18466898","doi":"10.1016/j.ejphar.2008.03.025","journal":"European journal of pharmacology","n_participants":null,"pmid":"18466898","source_url":"https://pubmed.ncbi.nlm.nih.gov/18466898/","study_design":null,"title":"GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid","title_match":true,"year":2008},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/hop-1-a-caenorhabditis-elegans-presenilin-appears-to-be-functionally-9342387","doi":"10.1073/pnas.94.22.12204","journal":"Proceedings of the National Academy of Sciences of the United States of America","n_participants":null,"pmid":"9342387","source_url":"https://pubmed.ncbi.nlm.nih.gov/9342387/","study_design":null,"title":"HOP-1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL-12 presenilin and to facilitate LIN-12 and GLP-1 signaling","title_match":true,"year":1997},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/neuroprotective-and-anti-apoptotic-effects-of-liraglutide-on-sh-sy5y-24112036","doi":"10.1111/jnc.12469","journal":"Journal of neurochemistry","n_participants":null,"pmid":"24112036","source_url":"https://pubmed.ncbi.nlm.nih.gov/24112036/","study_design":null,"title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-extra-pancreatic-effects-of-glp-1-receptor-agonists-a-focus-on-24373150","doi":"10.1111/dom.12251","journal":"Diabetes, obesity & metabolism","n_participants":null,"pmid":"24373150","source_url":"https://pubmed.ncbi.nlm.nih.gov/24373150/","study_design":null,"title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/evidence-for-a-physical-interaction-between-presenilin-and-notch-10077672","doi":"10.1073/pnas.96.6.3263","journal":"Proceedings of the National Academy of Sciences of the United States of America","n_participants":null,"pmid":"10077672","source_url":"https://pubmed.ncbi.nlm.nih.gov/10077672/","study_design":null,"title":"Evidence for a physical interaction between presenilin and Notch","title_match":false,"year":1999},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/gsk3-a-key-target-for-the-development-of-novel-treatments-for-type-2-22718609","doi":"10.1515/rns.2011.061","journal":"Reviews in the neurosciences","n_participants":null,"pmid":"22718609","source_url":"https://pubmed.ncbi.nlm.nih.gov/22718609/","study_design":null,"title":"GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease","title_match":false,"year":2011},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/diabetes-drugs-in-the-fight-against-alzheimer-s-disease-31330313","doi":"10.1016/j.arr.2019.100936","journal":"Ageing research reviews","n_participants":null,"pmid":"31330313","source_url":"https://pubmed.ncbi.nlm.nih.gov/31330313/","study_design":null,"title":"Diabetes drugs in the fight against Alzheimer's disease","title_match":false,"year":2019},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/the-nature-significance-and-glucagon-like-peptide-1-analog-treatment-24529520","doi":"10.1016/j.jalz.2013.12.007","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"24529520","source_url":"https://pubmed.ncbi.nlm.nih.gov/24529520/","study_design":null,"title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease","title_match":true,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/geniposide-a-novel-agonist-for-glp-1-receptor-prevents-pc12-cells-17629357","doi":"10.1016/j.neuint.2007.04.021","journal":"Neurochemistry international","n_participants":null,"pmid":"17629357","source_url":"https://pubmed.ncbi.nlm.nih.gov/17629357/","study_design":null,"title":"Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway","title_match":true,"year":2007},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/neural-correlates-of-liraglutide-effects-in-persons-at-risk-for-30099030","doi":"10.1016/j.bbr.2018.08.006","journal":"Behavioural brain research","n_participants":null,"pmid":"30099030","source_url":"https://pubmed.ncbi.nlm.nih.gov/30099030/","study_design":null,"title":"Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease","title_match":true,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/liraglutide-protects-against-amyloid-protein-induced-impairment-of-22592020","doi":"10.1016/j.neurobiolaging.2012.04.009","journal":"Neurobiology of aging","n_participants":null,"pmid":"22592020","source_url":"https://pubmed.ncbi.nlm.nih.gov/22592020/","study_design":null,"title":"Liraglutide protects against amyloid-\u03b2 protein-induced impairment of spatial learning and memory in rats","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/neuroprotective-properties-of-glp-1-theoretical-and-practical-21222567","doi":"10.1185/03007995.2010.549466","journal":"Current medical research and opinion","n_participants":null,"pmid":"21222567","source_url":"https://pubmed.ncbi.nlm.nih.gov/21222567/","study_design":null,"title":"Neuroprotective properties of GLP-1: theoretical and practical applications","title_match":true,"year":2011},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/vildagliptin-attenuates-huntington-s-disease-through-activation-of-31728850","doi":"10.1007/s13311-019-00805-5","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"31728850","source_url":"https://pubmed.ncbi.nlm.nih.gov/31728850/","study_design":null,"title":"Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model","title_match":true,"year":2020},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/a-new-treatment-strategy-for-parkinson-s-disease-through-the-gut-29113464","doi":"10.1177/0963689717721234","journal":"Cell transplantation","n_participants":null,"pmid":"29113464","source_url":"https://pubmed.ncbi.nlm.nih.gov/29113464/","study_design":null,"title":"A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway","title_match":true,"year":2017},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/vildagliptin-an-anti-diabetes-agent-ameliorates-cognitive-deficits-24117480","doi":"10.1111/jphp.12148","journal":"The Journal of pharmacy and pharmacology","n_participants":null,"pmid":"24117480","source_url":"https://pubmed.ncbi.nlm.nih.gov/24117480/","study_design":null,"title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease","title_match":false,"year":2013},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/exendin-4-ameliorates-motor-neuron-degeneration-in-cellular-and-22384126","doi":"10.1371/journal.pone.0032008","journal":"PloS one","n_participants":null,"pmid":"22384126","source_url":"https://pubmed.ncbi.nlm.nih.gov/22384126/","study_design":null,"title":"Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis","title_match":false,"year":2012},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/diabetes-drugs-and-neurological-disorders-new-views-and-therapeutic-24622756","doi":"10.1016/s2213-8587(13)70125-6","journal":"The lancet. Diabetes & endocrinology","n_participants":null,"pmid":"24622756","source_url":"https://pubmed.ncbi.nlm.nih.gov/24622756/","study_design":null,"title":"Diabetes drugs and neurological disorders: new views and therapeutic possibilities","title_match":false,"year":2014},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/incretin-and-insulin-signaling-as-novel-therapeutic-targets-for-36258018","doi":"10.1038/s41380-022-01792-4","journal":"Molecular psychiatry","n_participants":null,"pmid":"36258018","source_url":"https://pubmed.ncbi.nlm.nih.gov/36258018/","study_design":"clinical trial","title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","title_match":false,"year":2023},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-glp-1-protects-against-methylglyoxal-induced-19463904","doi":"10.1016/j.neuroscience.2009.05.025","journal":"Neuroscience","n_participants":null,"pmid":"19463904","source_url":"https://pubmed.ncbi.nlm.nih.gov/19463904/","study_design":null,"title":"Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway","title_match":true,"year":2009},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/fructooligosaccharides-ameliorating-cognitive-deficits-and-30816709","doi":"10.1021/acs.jafc.8b07313","journal":"Journal of agricultural and food chemistry","n_participants":null,"pmid":"30816709","source_url":"https://pubmed.ncbi.nlm.nih.gov/30816709/","study_design":null,"title":"Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota","title_match":false,"year":2019},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/protective-properties-of-glp-1-and-associated-peptide-hormones-in-33900631","doi":"10.1111/bph.15508","journal":"British journal of pharmacology","n_participants":null,"pmid":"33900631","source_url":"https://pubmed.ncbi.nlm.nih.gov/33900631/","study_design":null,"title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","title_match":true,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/chronic-treatment-with-the-glp1-analogue-liraglutide-increases-cell-23536825","doi":"10.1371/journal.pone.0058784","journal":"PloS one","n_participants":null,"pmid":"23536825","source_url":"https://pubmed.ncbi.nlm.nih.gov/23536825/","study_design":null,"title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/diabetes-as-a-risk-factor-for-alzheimer-s-disease-insulin-signalling-21787319","doi":"10.1042/bst0390891","journal":"Biochemical Society transactions","n_participants":null,"pmid":"21787319","source_url":"https://pubmed.ncbi.nlm.nih.gov/21787319/","study_design":null,"title":"Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease","title_match":false,"year":2011},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/glp-1-s-role-in-neuroprotection-a-systematic-review-30938196","doi":"10.1080/02699052.2019.1587000","journal":"Brain injury","n_participants":null,"pmid":"30938196","source_url":"https://pubmed.ncbi.nlm.nih.gov/30938196/","study_design":"systematic review","title":"GLP-1's role in neuroprotection: a systematic review","title_match":true,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/activation-of-glucagon-like-peptide-1-receptor-promotes-28456941","doi":"10.1007/s12035-017-0550-2","journal":"Molecular neurobiology","n_participants":null,"pmid":"28456941","source_url":"https://pubmed.ncbi.nlm.nih.gov/28456941/","study_design":null,"title":"Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses","title_match":true,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/prophylactic-liraglutide-treatment-prevents-amyloid-plaque-deposition-26205827","doi":"10.1016/j.bbr.2015.07.024","journal":"Behavioural brain research","n_participants":null,"pmid":"26205827","source_url":"https://pubmed.ncbi.nlm.nih.gov/26205827/","study_design":null,"title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice","title_match":true,"year":2015},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/saxagliptin-a-novel-antiparkinsonian-approach-25446674","doi":"10.1016/j.neuropharm.2014.10.007","journal":"Neuropharmacology","n_participants":null,"pmid":"25446674","source_url":"https://pubmed.ncbi.nlm.nih.gov/25446674/","study_design":null,"title":"Saxagliptin: a novel antiparkinsonian approach","title_match":false,"year":2015},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/semaglutide-ameliorates-cognition-and-glucose-metabolism-dysfunction-37730113","doi":"10.1016/j.neuropharm.2023.109716","journal":"Neuropharmacology","n_participants":null,"pmid":"37730113","source_url":"https://pubmed.ncbi.nlm.nih.gov/37730113/","study_design":"clinical trial","title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway","title_match":true,"year":2023},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/subcutaneous-administration-of-liraglutide-ameliorates-learning-and-27131827","doi":"10.1016/j.ejphar.2016.04.052","journal":"European journal of pharmacology","n_participants":null,"pmid":"27131827","source_url":"https://pubmed.ncbi.nlm.nih.gov/27131827/","study_design":null,"title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced alzheimer disease mouse model","title_match":true,"year":2016},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/crosstalk-between-diabetes-and-brain-glucagon-like-peptide-1-mimetics-23314196","doi":"10.1016/j.bbadis.2013.01.008","journal":"Biochimica et biophysica acta","n_participants":null,"pmid":"23314196","source_url":"https://pubmed.ncbi.nlm.nih.gov/23314196/","study_design":null,"title":"Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-stimulation-as-a-means-of-20128800","doi":"10.1111/j.1476-5381.2009.00486.x","journal":"British journal of pharmacology","n_participants":null,"pmid":"20128800","source_url":"https://pubmed.ncbi.nlm.nih.gov/20128800/","study_design":null,"title":"Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection","title_match":true,"year":2010},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/nicastrin-binds-to-membrane-tethered-notch-11483961","doi":"10.1038/35087069","journal":"Nature cell biology","n_participants":null,"pmid":"11483961","source_url":"https://pubmed.ncbi.nlm.nih.gov/11483961/","study_design":null,"title":"Nicastrin binds to membrane-tethered Notch","title_match":false,"year":2001},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/linagliptin-a-dipeptidyl-peptidase-4-inhibitor-mitigates-cognitive-27699599","doi":"10.1007/s12035-016-0125-7","journal":"Molecular neurobiology","n_participants":null,"pmid":"27699599","source_url":"https://pubmed.ncbi.nlm.nih.gov/27699599/","study_design":null,"title":"Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease","title_match":false,"year":2017},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/the-incretin-hormones-glucagonlike-peptide-1-and-glucose-dependent-24529525","doi":"10.1016/j.jalz.2013.12.009","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"24529525","source_url":"https://pubmed.ncbi.nlm.nih.gov/24529525/","study_design":null,"title":"The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease","title_match":false,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-type-2-diabetes-drug-liraglutide-reduces-chronic-inflammation-23276669","doi":"10.1016/j.ejphar.2012.12.012","journal":"European journal of pharmacology","n_participants":null,"pmid":"23276669","source_url":"https://pubmed.ncbi.nlm.nih.gov/23276669/","study_design":null,"title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","title_match":true,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-mechanism-and-efficacy-of-glp-1-receptor-agonists-in-the-36465634","doi":"10.3389/fendo.2022.1033479","journal":"Frontiers in endocrinology","n_participants":null,"pmid":"36465634","source_url":"https://pubmed.ncbi.nlm.nih.gov/36465634/","study_design":null,"title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease","title_match":true,"year":2022},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/liraglutide-attenuates-the-depressive-and-anxiety-like-behaviour-in-29705602","doi":"10.1016/j.brainres.2018.04.031","journal":"Brain research","n_participants":null,"pmid":"29705602","source_url":"https://pubmed.ncbi.nlm.nih.gov/29705602/","study_design":null,"title":"Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity","title_match":true,"year":2018},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/crosstalk-between-advanced-glycation-end-products-ages-receptor-rage-25582643","doi":"10.1186/s12933-015-0176-5","journal":"Cardiovascular diabetology","n_participants":null,"pmid":"25582643","source_url":"https://pubmed.ncbi.nlm.nih.gov/25582643/","study_design":null,"title":"Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications","title_match":false,"year":2015},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/aberrant-subcellular-neuronal-calcium-regulation-in-aging-and-20950656","doi":"10.1016/j.bbamcr.2010.10.005","journal":"Biochimica et biophysica acta","n_participants":null,"pmid":"20950656","source_url":"https://pubmed.ncbi.nlm.nih.gov/20950656/","study_design":null,"title":"Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease","title_match":false,"year":2011},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/enhancing-central-nervous-system-endogenous-glp-1-receptor-pathways-15974903","doi":"10.2174/1567205054367892","journal":"Current Alzheimer research","n_participants":null,"pmid":"15974903","source_url":"https://pubmed.ncbi.nlm.nih.gov/15974903/","study_design":null,"title":"Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease","title_match":true,"year":2005},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lixisenatide-rescues-spatial-memory-and-synaptic-plasticity-from-24583037","doi":"10.1016/j.neuroscience.2014.02.022","journal":"Neuroscience","n_participants":null,"pmid":"24583037","source_url":"https://pubmed.ncbi.nlm.nih.gov/24583037/","study_design":null,"title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats","title_match":false,"year":2014},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/insulin-signaling-impairment-in-the-brain-as-a-risk-factor-in-31068799","doi":"10.3389/fnagi.2019.00088","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"31068799","source_url":"https://pubmed.ncbi.nlm.nih.gov/31068799/","study_design":null,"title":"Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease","title_match":false,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/val8-glucagon-like-peptide-1-protects-against-a1-40-induced-20727946","doi":"10.1016/j.neuroscience.2010.08.028","journal":"Neuroscience","n_participants":null,"pmid":"20727946","source_url":"https://pubmed.ncbi.nlm.nih.gov/20727946/","study_design":null,"title":"Val8-glucagon-like peptide-1 protects against A\u03b21-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats","title_match":true,"year":2010},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/therapeutic-potential-of-semaglutide-a-newer-glp-1-receptor-agonist-35650449","doi":"10.1007/s11095-022-03302-1","journal":"Pharmaceutical research","n_participants":null,"pmid":"35650449","source_url":"https://pubmed.ncbi.nlm.nih.gov/35650449/","study_design":null,"title":"Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review","title_match":true,"year":2022},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-neuroprotective-effects-of-glp-1-possible-treatments-for-23000536","doi":"10.1016/j.bbr.2012.09.021","journal":"Behavioural brain research","n_participants":null,"pmid":"23000536","source_url":"https://pubmed.ncbi.nlm.nih.gov/23000536/","study_design":null,"title":"The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders","title_match":true,"year":2013},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/newer-glucose-lowering-drugs-and-risk-of-dementia-a-systematic-review-36821780","doi":"10.1111/jgs.18306","journal":"Journal of the American Geriatrics Society","n_participants":819511,"pmid":"36821780","source_url":"https://pubmed.ncbi.nlm.nih.gov/36821780/","study_design":"meta-analysis","title":"Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies","title_match":false,"year":2023},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-and-acceptability-of-antidiabetic-agents-for-29790638","doi":"10.1111/dom.13373","journal":"Diabetes, obesity & metabolism","n_participants":4855,"pmid":"29790638","source_url":"https://pubmed.ncbi.nlm.nih.gov/29790638/","study_design":"meta-analysis","title":"Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis","title_match":false,"year":2018},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/insulin-resistance-and-exendin-4-treatment-for-multiple-system-atrophy-28334990","doi":"10.1093/brain/awx044","journal":"Brain : a journal of neurology","n_participants":null,"pmid":"28334990","source_url":"https://pubmed.ncbi.nlm.nih.gov/28334990/","study_design":null,"title":"Insulin resistance and exendin-4 treatment for multiple system atrophy","title_match":false,"year":2017},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/liraglutide-improves-memory-in-obese-patients-with-prediabetes-or-31965072","doi":"10.1038/s41366-020-0535-5","journal":"International journal of obesity (2005)","n_participants":20,"pmid":"31965072","source_url":"https://pubmed.ncbi.nlm.nih.gov/31965072/","study_design":null,"title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study","title_match":true,"year":2020},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/lixisenatide-reduces-amyloid-plaques-neurofibrillary-tangles-and-29175324","doi":"10.1016/j.bbrc.2017.11.114","journal":"Biochemical and biophysical research communications","n_participants":null,"pmid":"29175324","source_url":"https://pubmed.ncbi.nlm.nih.gov/29175324/","study_design":null,"title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease","title_match":false,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-cleavage-product-glp-1-9-36-amide-rescues-23035082","doi":"10.1523/jneurosci.2107-12.2012","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","n_participants":null,"pmid":"23035082","source_url":"https://pubmed.ncbi.nlm.nih.gov/23035082/","study_design":null,"title":"Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice","title_match":true,"year":2012},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/a-novel-dual-glp-1-and-gip-receptor-agonist-is-neuroprotective-in-the-26453833","doi":"10.1016/j.brainres.2015.09.035","journal":"Brain research","n_participants":null,"pmid":"26453833","source_url":"https://pubmed.ncbi.nlm.nih.gov/26453833/","study_design":null,"title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF","title_match":true,"year":2016},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/emerging-links-between-type-2-diabetes-and-alzheimer-s-disease-26069723","doi":"10.4239/wjd.v6.i5.744","journal":"World journal of diabetes","n_participants":null,"pmid":"26069723","source_url":"https://pubmed.ncbi.nlm.nih.gov/26069723/","study_design":"longitudinal study","title":"Emerging links between type 2 diabetes and Alzheimer's disease","title_match":false,"year":2015},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/liraglutide-improves-water-maze-learning-and-memory-performance-while-28382596","doi":"10.1007/s11064-017-2250-8","journal":"Neurochemical research","n_participants":null,"pmid":"28382596","source_url":"https://pubmed.ncbi.nlm.nih.gov/28382596/","study_design":null,"title":"Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice","title_match":true,"year":2017},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/incretin-analogues-that-have-been-developed-to-treat-type-2-diabetes-20337586","doi":"10.2174/157488910791213130","journal":"Recent patents on CNS drug discovery","n_participants":null,"pmid":"20337586","source_url":"https://pubmed.ncbi.nlm.nih.gov/20337586/","study_design":null,"title":"Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease","title_match":false,"year":2010},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/gip-has-neuroprotective-effects-in-alzheimer-and-parkinson-s-disease-31705913","doi":"10.1016/j.peptides.2019.170184","journal":"Peptides","n_participants":null,"pmid":"31705913","source_url":"https://pubmed.ncbi.nlm.nih.gov/31705913/","study_design":null,"title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models","title_match":false,"year":2020},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/exenatide-reduces-tnf-expression-and-improves-hippocampal-neuron-26386291","doi":"10.1016/j.ejphar.2015.09.024","journal":"European journal of pharmacology","n_participants":null,"pmid":"26386291","source_url":"https://pubmed.ncbi.nlm.nih.gov/26386291/","study_design":null,"title":"Exenatide reduces TNF-\u03b1 expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats","title_match":true,"year":2015},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/subcutaneous-administration-of-liraglutide-ameliorates-alzheimer-23948890","doi":"10.3233/jad-130491","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"23948890","source_url":"https://pubmed.ncbi.nlm.nih.gov/23948890/","study_design":null,"title":"Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes","title_match":true,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/chenodeoxycholic-acid-ameliorates-alcl-3-induced-alzheimer-s-disease-31137621","doi":"10.3390/molecules24101992","journal":"Molecules (Basel, Switzerland)","n_participants":null,"pmid":"31137621","source_url":"https://pubmed.ncbi.nlm.nih.gov/31137621/","study_design":null,"title":"Chenodeoxycholic Acid Ameliorates AlCl 3 -Induced Alzheimer's Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats","title_match":false,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-neuroprotection-of-liraglutide-on-alzheimer-like-learning-and-24008687","doi":"10.3233/jad-130584","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"24008687","source_url":"https://pubmed.ncbi.nlm.nih.gov/24008687/","study_design":null,"title":"The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/exendin-4-a-glucagon-like-peptide-1-receptor-agonist-prevents-mtbi-23059457","doi":"10.1016/j.expneurol.2012.10.001","journal":"Experimental neurology","n_participants":null,"pmid":"23059457","source_url":"https://pubmed.ncbi.nlm.nih.gov/23059457/","study_design":null,"title":"Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice","title_match":true,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-role-of-glucagon-like-peptide-1-receptor-agonists-glp-1-ra-in-35340338","doi":"10.2147/dddt.s348055","journal":"Drug design, development and therapy","n_participants":null,"pmid":"35340338","source_url":"https://pubmed.ncbi.nlm.nih.gov/35340338/","study_design":null,"title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases","title_match":true,"year":2022},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/a-new-alzheimer-s-disease-interventive-strategy-glp-1-15270203","doi":"10.2174/1389450043345245","journal":"Current drug targets","n_participants":null,"pmid":"15270203","source_url":"https://pubmed.ncbi.nlm.nih.gov/15270203/","study_design":null,"title":"A new Alzheimer's disease interventive strategy: GLP-1","title_match":true,"year":2004},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/glp-1-mimetics-and-cognition-33121988","doi":"10.1016/j.lfs.2020.118645","journal":"Life sciences","n_participants":null,"pmid":"33121988","source_url":"https://pubmed.ncbi.nlm.nih.gov/33121988/","study_design":null,"title":"GLP-1 mimetics and cognition","title_match":true,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-glp-1-receptor-agonist-liraglutide-reduces-pathology-specific-tau-26746341","doi":"10.1016/j.brainres.2015.12.052","journal":"Brain research","n_participants":18,"pmid":"26746341","source_url":"https://pubmed.ncbi.nlm.nih.gov/26746341/","study_design":null,"title":"The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy","title_match":true,"year":2016},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/insulin-incretins-and-other-growth-factors-as-potential-novel-24646283","doi":"10.1042/bst20140016","journal":"Biochemical Society transactions","n_participants":null,"pmid":"24646283","source_url":"https://pubmed.ncbi.nlm.nih.gov/24646283/","study_design":null,"title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","title_match":false,"year":2014},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/biomarkers-of-alzheimer-s-disease-among-mexican-americans-23313927","doi":"10.3233/jad-122074","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"23313927","source_url":"https://pubmed.ncbi.nlm.nih.gov/23313927/","study_design":null,"title":"Biomarkers of Alzheimer's disease among Mexican Americans","title_match":false,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/exendin-4-induced-glucagon-like-peptide-1-receptor-activation-22892942","doi":"10.1007/s11357-012-9464-0","journal":"Age (Dordrecht, Netherlands)","n_participants":null,"pmid":"22892942","source_url":"https://pubmed.ncbi.nlm.nih.gov/22892942/","study_design":null,"title":"Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice","title_match":true,"year":2013},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/brain-glp-1-igf-1-signaling-and-autophagy-mediate-exendin-4-28573460","doi":"10.1007/s12035-017-0622-3","journal":"Molecular neurobiology","n_participants":null,"pmid":"28573460","source_url":"https://pubmed.ncbi.nlm.nih.gov/28573460/","study_design":null,"title":"Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats","title_match":true,"year":2018},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/liraglutide-and-a-lipidized-analog-of-prolactin-releasing-peptide-30428311","doi":"10.1016/j.neuropharm.2018.11.002","journal":"Neuropharmacology","n_participants":null,"pmid":"30428311","source_url":"https://pubmed.ncbi.nlm.nih.gov/30428311/","study_design":null,"title":"Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of \u03b2-amyloid pathology","title_match":true,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/a-novel-glp-1-gip-dual-receptor-agonist-protects-from-6-ohda-lesion-28223210","doi":"10.1016/j.neuropharm.2017.02.013","journal":"Neuropharmacology","n_participants":null,"pmid":"28223210","source_url":"https://pubmed.ncbi.nlm.nih.gov/28223210/","study_design":null,"title":"A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease","title_match":true,"year":2017},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-glucagon-like-peptides-a-new-genre-in-therapeutic-targets-for-12515900","doi":"10.3233/jad-2002-4605","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"12515900","source_url":"https://pubmed.ncbi.nlm.nih.gov/12515900/","study_design":null,"title":"The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease","title_match":true,"year":2002},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/glp-1a-going-beyond-traditional-use-35054924","doi":"10.3390/ijms23020739","journal":"International journal of molecular sciences","n_participants":null,"pmid":"35054924","source_url":"https://pubmed.ncbi.nlm.nih.gov/35054924/","study_design":"systematic review","title":"GLP-1a: Going beyond Traditional Use","title_match":false,"year":2022},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/dulaglutide-ameliorates-stz-induced-ad-like-impairment-of-learning-30773255","doi":"10.1016/j.bbrc.2019.01.103","journal":"Biochemical and biophysical research communications","n_participants":null,"pmid":"30773255","source_url":"https://pubmed.ncbi.nlm.nih.gov/30773255/","study_design":null,"title":"Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2","title_match":true,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/novel-glp-1-glucagon-like-peptide-1-analogues-and-insulin-in-the-26666230","doi":"10.1007/s40263-015-0301-8","journal":"CNS drugs","n_participants":null,"pmid":"26666230","source_url":"https://pubmed.ncbi.nlm.nih.gov/26666230/","study_design":null,"title":"Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases","title_match":true,"year":2015},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/insulin-as-a-bridge-between-type-2-diabetes-and-alzheimer-disease-how-25071725","doi":"10.3389/fendo.2014.00110","journal":"Frontiers in endocrinology","n_participants":null,"pmid":"25071725","source_url":"https://pubmed.ncbi.nlm.nih.gov/25071725/","study_design":null,"title":"Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia","title_match":false,"year":2014},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/antidiabetic-drugs-for-the-risk-of-alzheimer-disease-in-patients-with-32162525","doi":"10.1177/1533317519899546","journal":"American journal of Alzheimer's disease and other dementias","n_participants":85,"pmid":"32162525","source_url":"https://pubmed.ncbi.nlm.nih.gov/32162525/","study_design":null,"title":"Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS","title_match":false,"year":2020},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/liraglutide-and-its-neuroprotective-properties-focus-on-possible-30823403","doi":"10.3390/ijms20051050","journal":"International journal of molecular sciences","n_participants":null,"pmid":"30823403","source_url":"https://pubmed.ncbi.nlm.nih.gov/30823403/","study_design":null,"title":"Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events","title_match":true,"year":2019},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/glp-1-improves-the-neuronal-supportive-ability-of-astrocytes-in-33895160","doi":"10.1016/j.bcp.2021.114578","journal":"Biochemical pharmacology","n_participants":null,"pmid":"33895160","source_url":"https://pubmed.ncbi.nlm.nih.gov/33895160/","study_design":null,"title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway","title_match":true,"year":2021},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-glp-1-likes-alzheimer-s-disease-29598932","doi":"10.1016/j.dsx.2018.03.002","journal":"Diabetes & metabolic syndrome","n_participants":null,"pmid":"29598932","source_url":"https://pubmed.ncbi.nlm.nih.gov/29598932/","study_design":null,"title":"Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease","title_match":true,"year":2018},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/role-of-glucagon-like-peptide-1-receptor-agonists-in-alzheimer-s-39501255","doi":"10.1186/s12929-024-01090-x","journal":"Journal of biomedical science","n_participants":null,"pmid":"39501255","source_url":"https://pubmed.ncbi.nlm.nih.gov/39501255/","study_design":null,"title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/semaglutide-attenuates-anxious-and-depressive-like-behaviors-and-39042202","doi":"10.1007/s11481-024-10142-w","journal":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","n_participants":null,"pmid":"39042202","source_url":"https://pubmed.ncbi.nlm.nih.gov/39042202/","study_design":null,"title":"Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis","title_match":true,"year":2024},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/new-roles-for-insulin-like-hormones-in-neuronal-signalling-and-18930564","doi":"10.1016/j.neurobiolaging.2008.08.023","journal":"Neurobiology of aging","n_participants":null,"pmid":"18930564","source_url":"https://pubmed.ncbi.nlm.nih.gov/18930564/","study_design":null,"title":"New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?","title_match":false,"year":2010},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/activation-of-glucagon-like-peptide-1-receptor-ameliorates-cognitive-34250817","doi":"10.1161/jaha.120.020734","journal":"Journal of the American Heart Association","n_participants":null,"pmid":"34250817","source_url":"https://pubmed.ncbi.nlm.nih.gov/34250817/","study_design":null,"title":"Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway","title_match":true,"year":2021},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/class-ii-g-protein-coupled-receptors-and-their-ligands-in-neuronal-16052036","doi":"10.1385/nmm:7:1-2:003","journal":"Neuromolecular medicine","n_participants":null,"pmid":"16052036","source_url":"https://pubmed.ncbi.nlm.nih.gov/16052036/","study_design":null,"title":"Class II G protein-coupled receptors and their ligands in neuronal function and protection","title_match":false,"year":2005},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/brain-uptake-pharmacokinetics-of-albiglutide-dulaglutide-tirzepatide-38095516","doi":"10.1080/21688370.2023.2292461","journal":"Tissue barriers","n_participants":null,"pmid":"38095516","source_url":"https://pubmed.ncbi.nlm.nih.gov/38095516/","study_design":null,"title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/liraglutide-protects-against-brain-amyloid-1-42-accumulation-in-32143329","doi":"10.3390/ijms21051746","journal":"International journal of molecular sciences","n_participants":null,"pmid":"32143329","source_url":"https://pubmed.ncbi.nlm.nih.gov/32143329/","study_design":null,"title":"Liraglutide Protects Against Brain Amyloid-\u03b2 1-42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation","title_match":true,"year":2020},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/reverse-genetic-analysis-of-caenorhabditis-elegans-presenilins-10051671","doi":"10.1073/pnas.96.5.2497","journal":"Proceedings of the National Academy of Sciences of the United States of America","n_participants":null,"pmid":"10051671","source_url":"https://pubmed.ncbi.nlm.nih.gov/10051671/","study_design":null,"title":"Reverse genetic analysis of Caenorhabditis elegans presenilins reveals redundant but unequal roles for sel-12 and hop-1 in Notch-pathway signaling","title_match":false,"year":1999},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-potential-role-of-human-islet-amyloid-polypeptide-in-type-2-37173803","doi":"10.1186/s13098-023-01082-1","journal":"Diabetology & metabolic syndrome","n_participants":null,"pmid":"37173803","source_url":"https://pubmed.ncbi.nlm.nih.gov/37173803/","study_design":null,"title":"The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases","title_match":false,"year":2023},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/role-of-insulin-receptor-substance-1-modulating-pi3k-akt-insulin-33927970","doi":"10.1007/s13205-021-02738-3","journal":"3 Biotech","n_participants":null,"pmid":"33927970","source_url":"https://pubmed.ncbi.nlm.nih.gov/33927970/","study_design":null,"title":"Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/semaglutide-mediated-protection-against-a-correlated-with-enhancement-33222922","doi":"10.1016/j.jocn.2020.09.054","journal":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","n_participants":null,"pmid":"33222922","source_url":"https://pubmed.ncbi.nlm.nih.gov/33222922/","study_design":null,"title":"Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis","title_match":true,"year":2020},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/dpp-4-inhibitor-improves-learning-and-memory-deficits-and-ad-like-31199957","doi":"10.1016/j.neuropharm.2019.107668","journal":"Neuropharmacology","n_participants":null,"pmid":"31199957","source_url":"https://pubmed.ncbi.nlm.nih.gov/31199957/","study_design":null,"title":"DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling","title_match":true,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/exenatide-alleviates-mitochondrial-dysfunction-and-cognitive-31082410","doi":"10.1016/j.bbr.2019.111932","journal":"Behavioural brain research","n_participants":null,"pmid":"31082410","source_url":"https://pubmed.ncbi.nlm.nih.gov/31082410/","study_design":null,"title":"Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5\u00d7FAD mouse model of Alzheimer's disease","title_match":true,"year":2019},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/one-for-all-hitting-multiple-alzheimer-s-disease-targets-with-one-drug-27199640","doi":"10.3389/fnins.2016.00177","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"27199640","source_url":"https://pubmed.ncbi.nlm.nih.gov/27199640/","study_design":null,"title":"One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug","title_match":false,"year":2016},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/exenatide-promotes-cognitive-enhancement-and-positive-brain-metabolic-23640454","doi":"10.1038/cddis.2013.139","journal":"Cell death & disease","n_participants":null,"pmid":"23640454","source_url":"https://pubmed.ncbi.nlm.nih.gov/23640454/","study_design":null,"title":"Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals","title_match":true,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/new-therapeutic-strategies-and-drug-candidates-for-neurodegenerative-15681814","doi":"10.1196/annals.1332.018","journal":"Annals of the New York Academy of Sciences","n_participants":null,"pmid":"15681814","source_url":"https://pubmed.ncbi.nlm.nih.gov/15681814/","study_design":null,"title":"New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists","title_match":true,"year":2004},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-effect-of-glp-1-engineered-strain-on-mice-model-of-32333225","doi":"10.1186/s13568-020-01014-6","journal":"AMB Express","n_participants":null,"pmid":"32333225","source_url":"https://pubmed.ncbi.nlm.nih.gov/32333225/","study_design":null,"title":"Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease","title_match":true,"year":2020},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/comparison-on-cognitive-outcomes-of-antidiabetic-agents-for-type-2-37302139","doi":"10.1002/dmrr.3673","journal":"Diabetes/metabolism research and reviews","n_participants":null,"pmid":"37302139","source_url":"https://pubmed.ncbi.nlm.nih.gov/37302139/","study_design":"meta-analysis","title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis","title_match":false,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-dual-glp-1-gip-receptor-agonist-da4-jc-shows-superior-protective-32959677","doi":"10.1177/1533317520953041","journal":"American journal of Alzheimer's disease and other dementias","n_participants":null,"pmid":"32959677","source_url":"https://pubmed.ncbi.nlm.nih.gov/32959677/","study_design":null,"title":"The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease","title_match":true,"year":2020},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/neuroprotective-actions-of-glucagon-like-peptide-1-glp-1-analogues-in-30511349","doi":"10.1007/s40263-018-0593-6","journal":"CNS drugs","n_participants":null,"pmid":"30511349","source_url":"https://pubmed.ncbi.nlm.nih.gov/30511349/","study_design":null,"title":"Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases","title_match":true,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/inflammation-insulin-signaling-and-cognitive-function-in-aged-app-ps1-29604345","doi":"10.1016/j.bbi.2018.03.032","journal":"Brain, behavior, and immunity","n_participants":null,"pmid":"29604345","source_url":"https://pubmed.ncbi.nlm.nih.gov/29604345/","study_design":null,"title":"Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice","title_match":false,"year":2018},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/da5-ch-a-novel-glp-1-gip-dual-agonist-effectively-ameliorates-the-29551659","doi":"10.1016/j.ejphar.2018.03.024","journal":"European journal of pharmacology","n_participants":null,"pmid":"29551659","source_url":"https://pubmed.ncbi.nlm.nih.gov/29551659/","study_design":null,"title":"DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease","title_match":true,"year":2018},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/diabetes-antidiabetic-medications-and-risk-of-dementia-a-systematic-37869901","doi":"10.1111/dom.15331","journal":"Diabetes, obesity & metabolism","n_participants":100,"pmid":"37869901","source_url":"https://pubmed.ncbi.nlm.nih.gov/37869901/","study_design":"meta-analysis","title":"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-importance-of-estradiol-for-body-weight-regulation-in-women-36419765","doi":"10.3389/fendo.2022.951186","journal":"Frontiers in endocrinology","n_participants":null,"pmid":"36419765","source_url":"https://pubmed.ncbi.nlm.nih.gov/36419765/","study_design":null,"title":"The importance of estradiol for body weight regulation in women","title_match":false,"year":2022},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/retracted-liraglutide-has-anti-inflammatory-and-anti-amyloid-33467075","doi":"10.3390/ijms22020860","journal":"International journal of molecular sciences","n_participants":null,"pmid":"33467075","source_url":"https://pubmed.ncbi.nlm.nih.gov/33467075/","study_design":null,"title":"RETRACTED: Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease","title_match":true,"year":2021},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-effect-on-cognitive-function-in-patients-with-37657738","doi":"10.1016/j.diabet.2023.101470","journal":"Diabetes & metabolism","n_participants":null,"pmid":"37657738","source_url":"https://pubmed.ncbi.nlm.nih.gov/37657738/","study_design":null,"title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","title_match":true,"year":2023},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/neuroprotective-effects-of-glucose-dependent-insulinotropic-26351802","doi":"10.1515/revneuro-2015-0021","journal":"Reviews in the neurosciences","n_participants":null,"pmid":"26351802","source_url":"https://pubmed.ncbi.nlm.nih.gov/26351802/","study_design":null,"title":"Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease","title_match":false,"year":2016},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/geniposide-mediated-protection-against-amyloid-deposition-and-30684442","doi":"10.18632/aging.101759","journal":"Aging","n_participants":null,"pmid":"30684442","source_url":"https://pubmed.ncbi.nlm.nih.gov/30684442/","study_design":null,"title":"Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease","title_match":false,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/a-novel-glp-1-gip-gcg-triagonist-reduces-cognitive-deficits-and-29473979","doi":"10.1002/hipo.22837","journal":"Hippocampus","n_participants":null,"pmid":"29473979","source_url":"https://pubmed.ncbi.nlm.nih.gov/29473979/","study_design":null,"title":"A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease","title_match":true,"year":2018},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-role-of-glucagon-like-peptide-1-glp1-in-type-3-diabetes-glp-1-29165354","doi":"10.3390/ijms18112493","journal":"International journal of molecular sciences","n_participants":null,"pmid":"29165354","source_url":"https://pubmed.ncbi.nlm.nih.gov/29165354/","study_design":null,"title":"The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain","title_match":true,"year":2017},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/incretin-mimetics-as-pharmacologic-tools-to-elucidate-and-as-a-new-24529527","doi":"10.1016/j.jalz.2013.12.011","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"24529527","source_url":"https://pubmed.ncbi.nlm.nih.gov/24529527/","study_design":null,"title":"Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury","title_match":false,"year":2014},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/tirzepatide-prevents-neurodegeneration-through-multiple-molecular-38287296","doi":"10.1186/s12967-024-04927-z","journal":"Journal of translational medicine","n_participants":null,"pmid":"38287296","source_url":"https://pubmed.ncbi.nlm.nih.gov/38287296/","study_design":null,"title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","title_match":true,"year":2024},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/tumor-necrosis-factor-induced-cerebral-insulin-resistance-in-22966039","doi":"10.1124/pr.112.005850","journal":"Pharmacological reviews","n_participants":null,"pmid":"22966039","source_url":"https://pubmed.ncbi.nlm.nih.gov/22966039/","study_design":null,"title":"Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales","title_match":false,"year":2012},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/neuroprotective-effects-of-glp-1-receptor-agonists-in-39486172","doi":"10.1016/j.intimp.2024.113537","journal":"International immunopharmacology","n_participants":102935,"pmid":"39486172","source_url":"https://pubmed.ncbi.nlm.nih.gov/39486172/","study_design":"cohort study","title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","title_match":true,"year":2024},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/exenatide-exerts-cognitive-effects-by-modulating-the-bdnf-trkb-29331730","doi":"10.1016/j.neurobiolaging.2017.12.009","journal":"Neurobiology of aging","n_participants":null,"pmid":"29331730","source_url":"https://pubmed.ncbi.nlm.nih.gov/29331730/","study_design":null,"title":"Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice","title_match":true,"year":2018},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/gut-brain-connection-the-neuroprotective-effects-of-the-anti-diabetic-26131323","doi":"10.4239/wjd.v6.i6.807","journal":"World journal of diabetes","n_participants":null,"pmid":"26131323","source_url":"https://pubmed.ncbi.nlm.nih.gov/26131323/","study_design":null,"title":"Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide","title_match":true,"year":2015},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-analogs-mitigate-neuroinflammation-in-34906628","doi":"10.1016/j.mce.2021.111529","journal":"Molecular and cellular endocrinology","n_participants":null,"pmid":"34906628","source_url":"https://pubmed.ncbi.nlm.nih.gov/34906628/","study_design":null,"title":"Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes","title_match":true,"year":2022},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/drug-development-for-alzheimer-s-disease-review-29732929","doi":"10.1080/1061186x.2018.1474361","journal":"Journal of drug targeting","n_participants":null,"pmid":"29732929","source_url":"https://pubmed.ncbi.nlm.nih.gov/29732929/","study_design":null,"title":"Drug development for Alzheimer's disease: review","title_match":false,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/early-intervention-with-glucagon-like-peptide-1-analog-liraglutide-26183127","doi":"10.1111/jnc.13248","journal":"Journal of neurochemistry","n_participants":27,"pmid":"26183127","source_url":"https://pubmed.ncbi.nlm.nih.gov/26183127/","study_design":null,"title":"Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice","title_match":true,"year":2015},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/mutated-recombinant-human-glucagon-like-peptide-1-protects-sh-sy5y-18760331","doi":"10.1016/j.neulet.2008.08.047","journal":"Neuroscience letters","n_participants":null,"pmid":"18760331","source_url":"https://pubmed.ncbi.nlm.nih.gov/18760331/","study_design":null,"title":"Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42)","title_match":true,"year":2008},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/the-neuroprotection-of-liraglutide-on-diabetic-cognitive-deficits-is-31201846","doi":"10.1016/j.lfs.2019.116566","journal":"Life sciences","n_participants":null,"pmid":"31201846","source_url":"https://pubmed.ncbi.nlm.nih.gov/31201846/","study_design":null,"title":"The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis","title_match":true,"year":2019},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/discovering-new-treatments-for-alzheimer-s-disease-by-repurposing-24059463","doi":"10.2174/15680266113136660162","journal":"Current topics in medicinal chemistry","n_participants":null,"pmid":"24059463","source_url":"https://pubmed.ncbi.nlm.nih.gov/24059463/","study_design":null,"title":"Discovering new treatments for Alzheimer's disease by repurposing approved medications","title_match":false,"year":2013},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-role-of-glp-1-in-neuronal-activity-and-neurodegeneration-21094907","doi":"10.1016/b978-0-12-381517-0.00013-8","journal":"Vitamins and hormones","n_participants":null,"pmid":"21094907","source_url":"https://pubmed.ncbi.nlm.nih.gov/21094907/","study_design":null,"title":"The role of GLP-1 in neuronal activity and neurodegeneration","title_match":true,"year":2010},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/clinical-evidence-for-glp-1-receptor-agonists-in-alzheimer-s-disease-38746639","doi":"10.3233/adr-230181","journal":"Journal of Alzheimer's disease reports","n_participants":1444,"pmid":"38746639","source_url":"https://pubmed.ncbi.nlm.nih.gov/38746639/","study_design":"systematic review","title":"Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review","title_match":true,"year":2024},{"alzhub_score":64,"alzhub_url":"https://alzhub.org/study/genetic-variation-in-targets-of-antidiabetic-drugs-and-alzheimer-35654594","doi":"10.1212/wnl.0000000000200771","journal":"Neurology","n_participants":326885,"pmid":"35654594","source_url":"https://pubmed.ncbi.nlm.nih.gov/35654594/","study_design":null,"title":"Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study","title_match":false,"year":2022},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-protects-hippocampal-neurons-against-advanced-24183963","doi":"10.1016/j.neuroscience.2013.10.038","journal":"Neuroscience","n_participants":null,"pmid":"24183963","source_url":"https://pubmed.ncbi.nlm.nih.gov/24183963/","study_design":null,"title":"Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation","title_match":true,"year":2014},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/exendin-4-protected-against-cognitive-dysfunction-in-hyperglycemic-22844396","doi":"10.1371/journal.pone.0039656","journal":"PloS one","n_participants":null,"pmid":"22844396","source_url":"https://pubmed.ncbi.nlm.nih.gov/22844396/","study_design":null,"title":"Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection","title_match":false,"year":2012},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/targeting-redox-imbalance-in-neurodegeneration-characterizing-the-37771773","doi":"10.7150/thno.86831","journal":"Theranostics","n_participants":null,"pmid":"37771773","source_url":"https://pubmed.ncbi.nlm.nih.gov/37771773/","study_design":null,"title":"Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-in-neurodegeneration-neurovascular-unit-in-35805109","doi":"10.3390/cells11132023","journal":"Cells","n_participants":null,"pmid":"35805109","source_url":"https://pubmed.ncbi.nlm.nih.gov/35805109/","study_design":null,"title":"GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight","title_match":true,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-clinical-trials-to-watch-40782673","doi":"10.1016/j.medj.2025.100771","journal":"Med (New York, N.Y.)","n_participants":null,"pmid":"40782673","source_url":"https://pubmed.ncbi.nlm.nih.gov/40782673/","study_design":null,"title":"Alzheimer's disease: Clinical trials to watch","title_match":false,"year":2025},{"alzhub_score":89,"alzhub_url":"https://alzhub.org/study/medications-for-adults-with-type-2-diabetes-a-living-systematic-40813122","doi":"10.1136/bmj-2024-083039","journal":"BMJ (Clinical research ed.)","n_participants":168,"pmid":"40813122","source_url":"https://pubmed.ncbi.nlm.nih.gov/40813122/","study_design":"systematic review","title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/tirzepatide-a-novel-therapeutic-approach-for-alzheimer-s-disease-40498212","doi":"10.1007/s11011-025-01649-z","journal":"Metabolic brain disease","n_participants":null,"pmid":"40498212","source_url":"https://pubmed.ncbi.nlm.nih.gov/40498212/","study_design":null,"title":"Tirzepatide: a novel therapeutic approach for Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-in-neurodegenerative-40344943","doi":"10.1016/j.phrs.2025.107770","journal":"Pharmacological research","n_participants":null,"pmid":"40344943","source_url":"https://pubmed.ncbi.nlm.nih.gov/40344943/","study_design":null,"title":"Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/novel-lc-ms-ms-analysis-of-the-glp-1-analog-semaglutide-with-its-36989942","doi":"10.1016/j.jchromb.2023.123688","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","n_participants":null,"pmid":"36989942","source_url":"https://pubmed.ncbi.nlm.nih.gov/36989942/","study_design":null,"title":"Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-a-new-pharmacological-40042613","doi":"10.1007/s00115-025-01813-x","journal":"Der Nervenarzt","n_participants":null,"pmid":"40042613","source_url":"https://pubmed.ncbi.nlm.nih.gov/40042613/","study_design":null,"title":"[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-expanding-role-of-semaglutide-beyond-glycemic-control-40620322","doi":"10.1007/s40200-025-01663-z","journal":"Journal of diabetes and metabolic disorders","n_participants":null,"pmid":"40620322","source_url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","study_design":null,"title":"The expanding role of semaglutide: beyond glycemic control","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-and-the-degenerating-brain-exploring-mechanistic-insights-and-41226780","doi":"10.3390/ijms262110743","journal":"International journal of molecular sciences","n_participants":null,"pmid":"41226780","source_url":"https://pubmed.ncbi.nlm.nih.gov/41226780/","study_design":null,"title":"GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/are-glucagon-like-peptide-1-glp-1-receptor-agonists-central-nervous-40172827","doi":"10.1007/s40120-025-00724-y","journal":"Neurology and therapy","n_participants":null,"pmid":"40172827","source_url":"https://pubmed.ncbi.nlm.nih.gov/40172827/","study_design":null,"title":"Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/semaglutide-double-edged-sword-with-risks-and-benefits-39902055","doi":"10.26502/aimr.0189","journal":"Archives of internal medicine research","n_participants":null,"pmid":"39902055","source_url":"https://pubmed.ncbi.nlm.nih.gov/39902055/","study_design":null,"title":"Semaglutide: Double-edged Sword with Risks and Benefits","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/semaglutide-ameliorates-alzheimer-s-disease-and-restores-oxytocin-in-39405916","doi":"10.1016/j.biopha.2024.117540","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","n_participants":null,"pmid":"39405916","source_url":"https://pubmed.ncbi.nlm.nih.gov/39405916/","study_design":null,"title":"Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/from-metabolism-to-mind-the-expanding-role-of-the-glp-1-receptor-in-40738791","doi":"10.1016/j.neurot.2025.e00712","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"40738791","source_url":"https://pubmed.ncbi.nlm.nih.gov/40738791/","study_design":null,"title":"From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/oral-glp-1-receptor-agonist-promotes-astrocyte-neuron-lactate-and-42330959","doi":"10.1016/j.cmet.2026.05.014","journal":"Cell metabolism","n_participants":null,"pmid":"42330959","source_url":"https://pubmed.ncbi.nlm.nih.gov/42330959/","study_design":null,"title":"Oral GLP-1 receptor agonist promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects","title_match":true,"year":2026},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/exendin-4-reduces-tau-hyperphosphorylation-in-type-2-diabetic-rats-26640240","doi":"10.1016/j.mcn.2015.10.005","journal":"Molecular and cellular neurosciences","n_participants":null,"pmid":"26640240","source_url":"https://pubmed.ncbi.nlm.nih.gov/26640240/","study_design":null,"title":"Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level","title_match":false,"year":2016},{"alzhub_score":88,"alzhub_url":"https://alzhub.org/study/the-pharmacodynamics-based-prophylactic-benefits-of-glp-1-receptor-40189519","doi":"10.1186/s12916-025-04018-w","journal":"BMC medicine","n_participants":138282,"pmid":"40189519","source_url":"https://pubmed.ncbi.nlm.nih.gov/40189519/","study_design":"meta-analysis","title":"The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-glp-1-medicines-semaglutide-and-tirzepatide-do-not-alter-disease-39216535","doi":"10.1016/j.molmet.2024.102019","journal":"Molecular metabolism","n_participants":null,"pmid":"39216535","source_url":"https://pubmed.ncbi.nlm.nih.gov/39216535/","study_design":null,"title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice","title_match":true,"year":2024},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/12-month-neurological-and-psychiatric-outcomes-of-semaglutide-use-for-39764175","doi":"10.1016/j.eclinm.2024.102726","journal":"EClinicalMedicine","n_participants":23386,"pmid":"39764175","source_url":"https://pubmed.ncbi.nlm.nih.gov/39764175/","study_design":"cohort study","title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/incretin-hormones-glp-1-and-gip-normalize-energy-utilization-and-40938528","doi":"10.1007/s40263-025-01226-z","journal":"CNS drugs","n_participants":null,"pmid":"40938528","source_url":"https://pubmed.ncbi.nlm.nih.gov/40938528/","study_design":null,"title":"Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies","title_match":true,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/semaglutide-attenuates-neuroinflammation-in-male-mice-42265098","doi":"10.1038/s41467-026-74038-4","journal":"Nature communications","n_participants":null,"pmid":"42265098","source_url":"https://pubmed.ncbi.nlm.nih.gov/42265098/","study_design":null,"title":"Semaglutide attenuates neuroinflammation in male mice","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/effects-of-glucagon-like-peptide-1-glp-1-analogs-in-the-hippocampus-35180937","doi":"10.1016/bs.vh.2021.12.005","journal":"Vitamins and hormones","n_participants":null,"pmid":"35180937","source_url":"https://pubmed.ncbi.nlm.nih.gov/35180937/","study_design":null,"title":"Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus","title_match":true,"year":2022},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/effects-of-glp-1-receptor-agonists-on-neurological-complications-of-37231200","doi":"10.1007/s11154-023-09807-3","journal":"Reviews in endocrine & metabolic disorders","n_participants":19,"pmid":"37231200","source_url":"https://pubmed.ncbi.nlm.nih.gov/37231200/","study_design":"systematic review","title":"Effects of GLP-1 receptor agonists on neurological complications of diabetes","title_match":true,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-and-brain-vascular-function-34479819","doi":"10.1016/j.hlc.2021.07.024","journal":"Heart, lung & circulation","n_participants":null,"pmid":"34479819","source_url":"https://pubmed.ncbi.nlm.nih.gov/34479819/","study_design":null,"title":"Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function","title_match":true,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonist-semaglutide-ameliorates-motor-deficits-and-tau-40882702","doi":"10.1016/j.neuropharm.2025.110659","journal":"Neuropharmacology","n_participants":null,"pmid":"40882702","source_url":"https://pubmed.ncbi.nlm.nih.gov/40882702/","study_design":null,"title":"GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model","title_match":true,"year":2025},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/real-world-observations-of-glp-1-receptor-agonists-and-sglt-2-40898408","doi":"10.1002/alz.70639","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"40898408","source_url":"https://pubmed.ncbi.nlm.nih.gov/40898408/","study_design":null,"title":"Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/impacts-of-tirzepatide-on-older-patients-with-diminished-cell-40001315","doi":"10.1111/ggi.70018","journal":"Geriatrics & gerontology international","n_participants":null,"pmid":"40001315","source_url":"https://pubmed.ncbi.nlm.nih.gov/40001315/","study_design":null,"title":"Impacts of tirzepatide on older patients with diminished \u03b2-cell function and dementia","title_match":true,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/pancreatic-islet-of-langerhans-revisited-31020988","doi":"10.14670/hh-18-118","journal":"Histology and histopathology","n_participants":null,"pmid":"31020988","source_url":"https://pubmed.ncbi.nlm.nih.gov/31020988/","study_design":null,"title":"Pancreatic islet (of Langerhans) revisited","title_match":false,"year":2019},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/role-of-liraglutide-in-alzheimer-s-disease-pathology-34118986","doi":"10.1186/s13195-021-00853-0","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"34118986","source_url":"https://pubmed.ncbi.nlm.nih.gov/34118986/","study_design":null,"title":"Role of liraglutide in Alzheimer's disease pathology","title_match":true,"year":2021},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/incretin-based-therapy-of-metabolic-disease-36629298","doi":null,"journal":"Danish medical journal","n_participants":null,"pmid":"36629298","source_url":"https://pubmed.ncbi.nlm.nih.gov/36629298/","study_design":null,"title":"Incretin-based therapy of metabolic disease","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/cvot-summit-report-2023-new-cardiovascular-kidney-and-metabolic-38504284","doi":"10.1186/s12933-024-02180-8","journal":"Cardiovascular diabetology","n_participants":null,"pmid":"38504284","source_url":"https://pubmed.ncbi.nlm.nih.gov/38504284/","study_design":null,"title":"CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/the-metabolic-brain-axis-glp-1-signaling-insulin-resistance-and-42962966","doi":"10.1016/j.metabol.2026.156810","journal":"Metabolism: clinical and experimental","n_participants":null,"pmid":"42962966","source_url":"https://pubmed.ncbi.nlm.nih.gov/42962966/","study_design":"clinical trial","title":"The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration","title_match":true,"year":2026},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/association-between-exenatide-use-and-incidence-of-alzheimer-s-disease-33614900","doi":"10.1002/trc2.12139","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":342608,"pmid":"33614900","source_url":"https://pubmed.ncbi.nlm.nih.gov/33614900/","study_design":"retrospective cohort","title":"Association between exenatide use and incidence of Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/effect-of-glucagon-like-peptide-1-receptor-agonists-glp-1-ra-on-41862354","doi":"10.1016/j.clinthera.2026.02.010","journal":"Clinical therapeutics","n_participants":null,"pmid":"41862354","source_url":"https://pubmed.ncbi.nlm.nih.gov/41862354/","study_design":"systematic review","title":"Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-therapy-from-discovery-to-type-2-diabetes-and-36740965","doi":"10.3803/enm.2022.1642","journal":"Endocrinology and metabolism (Seoul, Korea)","n_participants":null,"pmid":"36740965","source_url":"https://pubmed.ncbi.nlm.nih.gov/36740965/","study_design":null,"title":"Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond","title_match":true,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/liraglutide-reduces-oxidative-stress-and-improves-energy-metabolism-35985417","doi":"10.1016/j.neuro.2022.08.007","journal":"Neurotoxicology","n_participants":null,"pmid":"35985417","source_url":"https://pubmed.ncbi.nlm.nih.gov/35985417/","study_design":null,"title":"Liraglutide reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/alternative-role-of-glucagon-like-peptide-1-receptor-agonists-in-36470445","doi":"10.1016/j.ejphar.2022.175439","journal":"European journal of pharmacology","n_participants":null,"pmid":"36470445","source_url":"https://pubmed.ncbi.nlm.nih.gov/36470445/","study_design":null,"title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","title_match":true,"year":2023},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/long-acting-exenatide-does-not-prevent-cognitive-decline-in-mild-38565814","doi":"10.1007/s40618-024-02320-7","journal":"Journal of endocrinological investigation","n_participants":17,"pmid":"38565814","source_url":"https://pubmed.ncbi.nlm.nih.gov/38565814/","study_design":null,"title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-in-neurodegenerative-40964464","doi":"10.7759/cureus.92441","journal":"Cureus","n_participants":null,"pmid":"40964464","source_url":"https://pubmed.ncbi.nlm.nih.gov/40964464/","study_design":null,"title":"Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/diabetes-risk-factor-and-translational-therapeutic-implications-for-35128745","doi":"10.1111/ejn.15619","journal":"The European journal of neuroscience","n_participants":null,"pmid":"35128745","source_url":"https://pubmed.ncbi.nlm.nih.gov/35128745/","study_design":null,"title":"Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease","title_match":false,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-inhibit-the-initiation-of-42133988","doi":"10.1021/jacs.6c01289","journal":"Journal of the American Chemical Society","n_participants":null,"pmid":"42133988","source_url":"https://pubmed.ncbi.nlm.nih.gov/42133988/","study_design":null,"title":"Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-\u03b242 Aggregation","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-derivatives-with-functional-sequences-transit-and-migrate-38185192","doi":"10.1016/j.ejpb.2024.114176","journal":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","n_participants":null,"pmid":"38185192","source_url":"https://pubmed.ncbi.nlm.nih.gov/38185192/","study_design":null,"title":"GLP-1 derivatives with functional sequences transit and migrate through trigeminal neurons","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/glp-1-and-underlying-beneficial-actions-in-alzheimer-s-disease-34552561","doi":"10.3389/fendo.2021.721198","journal":"Frontiers in endocrinology","n_participants":null,"pmid":"34552561","source_url":"https://pubmed.ncbi.nlm.nih.gov/34552561/","study_design":null,"title":"GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/the-role-of-glp-1-gip-receptor-agonists-in-alzheimer-s-disease-32614526","doi":"10.17219/acem/121007","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"32614526","source_url":"https://pubmed.ncbi.nlm.nih.gov/32614526/","study_design":null,"title":"The role of GLP-1/GIP receptor agonists in Alzheimer's disease","title_match":true,"year":2020},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/brain-imaging-of-the-glp-1-receptor-in-obesity-using-68ga-nodaga-34942949","doi":"10.3390/brainsci11121647","journal":"Brain sciences","n_participants":null,"pmid":"34942949","source_url":"https://pubmed.ncbi.nlm.nih.gov/34942949/","study_design":null,"title":"Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET","title_match":true,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-beyond-diabetes-what-the-neurosurgeon-needs-39959894","doi":"10.1227/neuprac.0000000000000098","journal":"Neurosurgery practice","n_participants":null,"pmid":"39959894","source_url":"https://pubmed.ncbi.nlm.nih.gov/39959894/","study_design":null,"title":"GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/reduced-glp-1r-availability-in-the-caudate-nucleus-with-alzheimer-s-38915346","doi":"10.3389/fnagi.2024.1350239","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"38915346","source_url":"https://pubmed.ncbi.nlm.nih.gov/38915346/","study_design":null,"title":"Reduced GLP-1R availability in the caudate nucleus with Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-cleavage-product-improves-cognitive-function-31040160","doi":"10.1523/eneuro.0031-19.2019","journal":"eNeuro","n_participants":null,"pmid":"31040160","source_url":"https://pubmed.ncbi.nlm.nih.gov/31040160/","study_design":null,"title":"Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome","title_match":true,"year":2019},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/neurodegeneration-onset-with-glucagon-like-peptide-1-receptor-41204243","doi":"10.1186/s12933-025-02962-8","journal":"Cardiovascular diabetology","n_participants":null,"pmid":"41204243","source_url":"https://pubmed.ncbi.nlm.nih.gov/41204243/","study_design":"cohort study","title":"Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study","title_match":true,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/mirtazapine-for-gastrointestinal-side-effects-of-glucagon-like-41388533","doi":"10.2478/enr-2025-0030","journal":"Endocrine regulations","n_participants":null,"pmid":"41388533","source_url":"https://pubmed.ncbi.nlm.nih.gov/41388533/","study_design":"case report","title":"Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/incretin-mimetics-as-potential-disease-modifying-treatment-for-39422964","doi":"10.3233/jad-240730","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"39422964","source_url":"https://pubmed.ncbi.nlm.nih.gov/39422964/","study_design":null,"title":"Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/incretin-based-multi-agonist-peptides-are-neuroprotective-and-anti-39062586","doi":"10.3390/biom14070872","journal":"Biomolecules","n_participants":null,"pmid":"39062586","source_url":"https://pubmed.ncbi.nlm.nih.gov/39062586/","study_design":null,"title":"Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-signaling-restores-aquaporin-4-subcellular-39577079","doi":"10.1016/j.bbrc.2024.151016","journal":"Biochemical and biophysical research communications","n_participants":null,"pmid":"39577079","source_url":"https://pubmed.ncbi.nlm.nih.gov/39577079/","study_design":null,"title":"GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid \u03b2 clearance in a mouse model of Alzheimer's disease","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-exciting-avenues-beyond-40142784","doi":"10.3390/jcm14061978","journal":"Journal of clinical medicine","n_participants":null,"pmid":"40142784","source_url":"https://pubmed.ncbi.nlm.nih.gov/40142784/","study_design":null,"title":"Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss","title_match":true,"year":2025},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/inflammatory-proteins-associated-with-alzheimer-s-disease-reduced-by-39358806","doi":"10.1186/s13195-024-01573-x","journal":"Alzheimer's research & therapy","n_participants":13752,"pmid":"39358806","source_url":"https://pubmed.ncbi.nlm.nih.gov/39358806/","study_design":null,"title":"Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","title_match":true,"year":2024},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/prolonged-drug-releasing-fibers-attenuate-alzheimer-s-disease-like-30298718","doi":"10.1021/acsami.8b12649","journal":"ACS applied materials & interfaces","n_participants":null,"pmid":"30298718","source_url":"https://pubmed.ncbi.nlm.nih.gov/30298718/","study_design":null,"title":"Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis","title_match":false,"year":2018},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/glp-1-analogue-liraglutide-attenuates-cih-induced-cognitive-deficits-39321702","doi":"10.1016/j.intimp.2024.113222","journal":"International immunopharmacology","n_participants":null,"pmid":"39321702","source_url":"https://pubmed.ncbi.nlm.nih.gov/39321702/","study_design":null,"title":"GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-\u03baB signaling pathways","title_match":true,"year":2024},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/expression-of-glp-1-receptors-in-insulin-containing-interneurons-of-30637442","doi":"10.1007/s00125-018-4803-z","journal":"Diabetologia","n_participants":null,"pmid":"30637442","source_url":"https://pubmed.ncbi.nlm.nih.gov/30637442/","study_design":null,"title":"Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex","title_match":true,"year":2019},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/liraglutide-for-psychiatric-disorders-clinical-evidence-and-challenges-30020885","doi":"10.1515/hmbci-2018-0031","journal":"Hormone molecular biology and clinical investigation","n_participants":null,"pmid":"30020885","source_url":"https://pubmed.ncbi.nlm.nih.gov/30020885/","study_design":null,"title":"Liraglutide for psychiatric disorders: clinical evidence and challenges","title_match":true,"year":2018},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/therapeutic-potential-of-spinal-glp-1-receptor-signaling-29329976","doi":"10.1016/j.peptides.2018.01.003","journal":"Peptides","n_participants":null,"pmid":"29329976","source_url":"https://pubmed.ncbi.nlm.nih.gov/29329976/","study_design":null,"title":"Therapeutic potential of spinal GLP-1 receptor signaling","title_match":true,"year":2018},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-to-expand-the-healthy-37191234","doi":"10.1111/acel.13818","journal":"Aging cell","n_participants":null,"pmid":"37191234","source_url":"https://pubmed.ncbi.nlm.nih.gov/37191234/","study_design":null,"title":"Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials","title_match":true,"year":2023},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/gut-microbiota-modification-via-glucagon-like-peptide-1-with-36619150","doi":"10.34172/mejdd.2022.278","journal":"Middle East journal of digestive diseases","n_participants":null,"pmid":"36619150","source_url":"https://pubmed.ncbi.nlm.nih.gov/36619150/","study_design":"systematic review","title":"Gut Microbiota Modification via Glucagon-like Peptide-1 with Beneficial Neuroprotective Effects","title_match":true,"year":2022},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/protective-effects-of-incretin-against-age-related-diseases-31622202","doi":"10.2174/1567201816666191010145029","journal":"Current drug delivery","n_participants":null,"pmid":"31622202","source_url":"https://pubmed.ncbi.nlm.nih.gov/31622202/","study_design":null,"title":"Protective Effects of Incretin Against Age-Related Diseases","title_match":false,"year":2019},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-potential-game-changers-in-35264926","doi":"10.3389/fnins.2022.824054","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"35264926","source_url":"https://pubmed.ncbi.nlm.nih.gov/35264926/","study_design":null,"title":"Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/potential-new-therapeutic-target-for-alzheimer-s-disease-glucagon-34676939","doi":"10.1111/ejn.15502","journal":"The European journal of neuroscience","n_participants":null,"pmid":"34676939","source_url":"https://pubmed.ncbi.nlm.nih.gov/34676939/","study_design":null,"title":"Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/liraglutide-ameliorates-hyperhomocysteinemia-induced-alzheimer-like-30632006","doi":"10.1007/s12264-018-00336-7","journal":"Neuroscience bulletin","n_participants":null,"pmid":"30632006","source_url":"https://pubmed.ncbi.nlm.nih.gov/30632006/","study_design":null,"title":"Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting","title_match":true,"year":2019},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/recent-advances-in-understanding-the-role-of-glucagon-like-peptide-1-32269764","doi":"10.12688/f1000research.20602.1","journal":"F1000Research","n_participants":null,"pmid":"32269764","source_url":"https://pubmed.ncbi.nlm.nih.gov/32269764/","study_design":null,"title":"Recent advances in understanding the role of glucagon-like peptide 1","title_match":true,"year":2020},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-and-mental-health-a-41025359","doi":"10.12701/jyms.2025.42.61","journal":"Journal of Yeungnam medical science","n_participants":null,"pmid":"41025359","source_url":"https://pubmed.ncbi.nlm.nih.gov/41025359/","study_design":"cohort study","title":"Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/semaglutide-and-the-pathogenesis-of-progressive-neurodegenerative-41047006","doi":"10.1016/j.yfrne.2025.101217","journal":"Frontiers in neuroendocrinology","n_participants":null,"pmid":"41047006","source_url":"https://pubmed.ncbi.nlm.nih.gov/41047006/","study_design":null,"title":"Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria","title_match":true,"year":2025},{"alzhub_score":73,"alzhub_url":"https://alzhub.org/study/use-of-glucagon-like-peptide-1-receptor-agonists-and-risk-of-41994910","doi":"10.1111/dom.70760","journal":"Diabetes, obesity & metabolism","n_participants":158,"pmid":"41994910","source_url":"https://pubmed.ncbi.nlm.nih.gov/41994910/","study_design":"cohort study","title":"Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/expression-of-concern-paladugu-et-al-liraglutide-has-anti-40429612","doi":"10.3390/ijms26104467","journal":"International journal of molecular sciences","n_participants":null,"pmid":"40429612","source_url":"https://pubmed.ncbi.nlm.nih.gov/40429612/","study_design":null,"title":"Expression of Concern: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860","title_match":true,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/incretin-based-drugs-and-the-risk-of-dementia-among-patients-with-41123870","doi":"10.1007/s40264-025-01623-9","journal":"Drug safety","n_participants":null,"pmid":"41123870","source_url":"https://pubmed.ncbi.nlm.nih.gov/41123870/","study_design":null,"title":"Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes","title_match":false,"year":2026},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/therapeutic-strategies-for-alzheimer-s-disease-in-the-view-of-31062332","doi":"10.1007/978-981-13-3540-2_11","journal":"Advances in experimental medicine and biology","n_participants":null,"pmid":"31062332","source_url":"https://pubmed.ncbi.nlm.nih.gov/31062332/","study_design":null,"title":"Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus","title_match":false,"year":2019},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-protects-synaptic-and-learning-functions-from-24464856","doi":"10.1002/jnr.23335","journal":"Journal of neuroscience research","n_participants":null,"pmid":"24464856","source_url":"https://pubmed.ncbi.nlm.nih.gov/24464856/","study_design":null,"title":"Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents","title_match":true,"year":2014},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-inflammatory-effects-of-glp-1-receptor-activation-in-the-brain-36076972","doi":"10.3390/ijms23179583","journal":"International journal of molecular sciences","n_participants":null,"pmid":"36076972","source_url":"https://pubmed.ncbi.nlm.nih.gov/36076972/","study_design":null,"title":"Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/crosstalk-between-alzheimer-s-disease-and-diabetes-a-focus-on-anti-37335453","doi":"10.1007/s11011-023-01225-3","journal":"Metabolic brain disease","n_participants":null,"pmid":"37335453","source_url":"https://pubmed.ncbi.nlm.nih.gov/37335453/","study_design":null,"title":"Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs","title_match":false,"year":2023},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/drug-repositioning-for-alzheimer-s-disease-finding-hidden-clues-in-32144994","doi":"10.3233/jad-200049","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"32144994","source_url":"https://pubmed.ncbi.nlm.nih.gov/32144994/","study_design":null,"title":"Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs","title_match":false,"year":2020},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/sodium-glucose-cotransporter-2-inhibitors-dulaglutide-and-risk-for-39186787","doi":"10.7326/m23-3220","journal":"Annals of internal medicine","n_participants":489,"pmid":"39186787","source_url":"https://pubmed.ncbi.nlm.nih.gov/39186787/","study_design":null,"title":"Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study","title_match":true,"year":2024},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/approach-toward-diabetes-treatment-in-the-elderly-32377065","doi":"10.14744/semb.2019.00868","journal":"Sisli Etfal Hastanesi tip bulteni","n_participants":null,"pmid":"32377065","source_url":"https://pubmed.ncbi.nlm.nih.gov/32377065/","study_design":null,"title":"Approach Toward Diabetes Treatment in the Elderly","title_match":false,"year":2019},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/foresee-novel-targets-for-alzheimer-s-disease-by-investigating-35733313","doi":"10.2174/1871527321666220622162622","journal":"CNS & neurological disorders drug targets","n_participants":null,"pmid":"35733313","source_url":"https://pubmed.ncbi.nlm.nih.gov/35733313/","study_design":null,"title":"Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs","title_match":false,"year":2023},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/linking-metabolic-syndrome-to-neurodegeneration-mechanisms-and-40272771","doi":"10.1007/s12035-025-04947-w","journal":"Molecular neurobiology","n_participants":null,"pmid":"40272771","source_url":"https://pubmed.ncbi.nlm.nih.gov/40272771/","study_design":"longitudinal study","title":"Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/oxidative-stress-aging-metabolism-sirt1-and-the-gut-microbiota-the-42545731","doi":"10.4103/mgr.medgasres-d-26-00073","journal":"Medical gas research","n_participants":null,"pmid":"42545731","source_url":"https://pubmed.ncbi.nlm.nih.gov/42545731/","study_design":null,"title":"Oxidative stress, aging, metabolism, SIRT1, and the gut microbiota: the neurocardiac basis of cognitive loss","title_match":false,"year":2027},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/beyond-glycemic-control-the-pleiotropic-role-of-glp-1ras-and-d34fac97","doi":"10.20944/preprints202610.2789.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202610.2789.v1","study_design":"narrative review","title":"Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/interventions-for-cognitive-impairment-in-type-2-diabetes-mellitus-an-da71abad","doi":"10.64898/2026.10.23.26366288","journal":"medRxiv","n_participants":213604,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.23.26366288","study_design":"meta-analysis","title":"Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/in-vivo-transcriptomics-based-framework-for-systematic-indication-2d6dd70a","doi":"10.64898/2026.10.12.758524","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.12.758524","study_design":null,"title":"In Vivo Transcriptomics-Based Framework for Systematic Indication Expansion","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/patterns-of-glp-1-receptor-agonist-initiation-compared-with-other-82f57b8f","doi":"10.64898/2026.09.29.26364340","journal":"medRxiv","n_participants":58754,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.29.26364340","study_design":"retrospective cohort","title":"Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/semaglutide-activates-the-orexin-hypocretin-and-basal-forebrain-d54ff148","doi":"10.64898/2026.08.03.742612","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.08.03.742612","study_design":null,"title":"Semaglutide Activates the Orexin/Hypocretin and Basal Forebrain Cholinergic Systems and Increases Acetylcholine Levels in the Hippocampus of Young and Aged Rats","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/glp-1-receptor-agonists-vs-sglt2-inhibitors-for-alzheimers-disease-e092d390","doi":"10.64898/2026.07.22.26358702","journal":"medRxiv","n_participants":12,"pmid":null,"source_url":"https://doi.org/10.64898/2026.07.22.26358702","study_design":"cohort study","title":"GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer\u2019s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/reversibility-and-access-a-two-axis-framework-for-glucagon-like-7e0e4d07","doi":"10.20944/preprints202607.1279.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202607.1279.v1","study_design":"clinical trial","title":"Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-receptor-agonists-and-risk-of-parkinsonian-0839901b","doi":"10.64898/2025.11.24.25340763","journal":"medRxiv","n_participants":11683,"pmid":null,"source_url":"https://doi.org/10.64898/2025.11.24.25340763","study_design":"cohort study","title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity","title_match":true,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/legacy-neuropsychiatric-benefit-after-semaglutide-is-linked-to-8d55012e","doi":"10.64898/2026.04.16.26351060","journal":"medRxiv","n_participants":63215,"pmid":null,"source_url":"https://doi.org/10.64898/2026.04.16.26351060","study_design":"longitudinal study","title":"Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/plasma-proteomic-analysis-of-apoe-4-homozygotes-identifies-827b8960","doi":"10.64898/2026.02.14.26346321","journal":"medRxiv","n_participants":413,"pmid":null,"source_url":"https://doi.org/10.64898/2026.02.14.26346321","study_design":null,"title":"Plasma Proteomic Analysis of APOE \u03b54 Homozygotes Identifies Preclinical Alzheimer\u2019s Disease Alterations Potentially Modulated by Semaglutide","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/functional-vs-cognitive-decline-heterogeneity-in-alzheimers-disease-44ef8278","doi":"10.20944/preprints202606.0711.v1","journal":"Preprints.org","n_participants":2169,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202606.0711.v1","study_design":null,"title":"Functional-vs-Cognitive Decline Heterogeneity in Alzheimer\u2019s Disease: LLM-Curation of Decades of Clinical Notes and GLP1RA Trial Design","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/beyond-cardiology-s-pillars-a-network-meta-analysis-comparing-the-e5966415","doi":"10.21203/rs.3.rs-9727771/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-9727771/v1","study_design":"systematic review","title":"Beyond Cardiology's Pillars: A Network Meta-Analysis Comparing the Recombinant Zoster Vaccine (Shingrix/RZV) with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Prevention of Major Adverse Cardiovascular Events and Dementia in Adults Aged \u226550 Years","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/semaglutide-attenuates-neuroinflammation-in-mice-a2d21860","doi":"10.64898/2026.01.10.698763","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.01.10.698763","study_design":null,"title":"Semaglutide Attenuates Neuroinflammation in Mice","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/beyond-glycemic-control-glp-1rabased-therapies-and-emerging-targets-fe439787","doi":"10.20944/preprints202602.0277.v1","journal":"Journal of clinical medicine","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202602.0277.v1","study_design":null,"title":"Beyond Glycemic Control: GLP-1RA\u2013Based Therapies and Emerging Targets Beyond the Metabolic Axis","title_match":false,"year":2026},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/pharmacologic-therapy-for-type-2-diabetes-mellitus-af75a470","doi":"10.7326/0003-4819-133-1-200007040-00016","journal":"Annals of Internal Medicine","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.7326/0003-4819-133-1-200007040-00016","study_design":"systematic review","title":"Pharmacologic Therapy for Type 2 Diabetes Mellitus","title_match":false,"year":2000},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/evaluation-of-liraglutide-in-the-treatment-of-alzheimer-s-disease-157ef668","doi":"10.1002/alz.057848","journal":"Alzheimer s & Dementia","n_participants":204,"pmid":null,"source_url":"https://doi.org/10.1002/alz.057848","study_design":null,"title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/liraglutide-suppresses-tau-hyperphosphorylation-amyloid-beta-32138327","doi":"10.3390/ijms21051725","journal":"International Journal of Molecular Sciences","n_participants":null,"pmid":"32138327","source_url":"https://pubmed.ncbi.nlm.nih.gov/32138327/","study_design":null,"title":"Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity","title_match":true,"year":2020},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/effect-of-liraglutide-on-cardiovascular-outcomes-in-elderly-patients-30508430","doi":"10.7326/m18-1569","journal":"Annals of Internal Medicine","n_participants":null,"pmid":"30508430","source_url":"https://pubmed.ncbi.nlm.nih.gov/30508430/","study_design":"randomized controlled trial","title":"Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial","title_match":true,"year":2018},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/long-term-treatment-with-liraglutide-a-glucagon-like-peptide-1-glp-1-27421117","doi":"10.1371/journal.pone.0158205","journal":"PLoS ONE","n_participants":null,"pmid":"27421117","source_url":"https://pubmed.ncbi.nlm.nih.gov/27421117/","study_design":null,"title":"Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on \u03b2-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer\u2019s Disease","title_match":true,"year":2016},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/liraglutide-restores-chronic-er-stress-autophagy-impairments-and-29170452","doi":"10.1038/s41598-017-16488-x","journal":"Scientific Reports","n_participants":null,"pmid":"29170452","source_url":"https://pubmed.ncbi.nlm.nih.gov/29170452/","study_design":null,"title":"Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells","title_match":true,"year":2017},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/the-caenorhabditis-elegans-impas-gene-imp-2-is-essential-for-15469912","doi":"10.1073/pnas.0406462101","journal":"Proceedings of the National Academy of Sciences","n_participants":null,"pmid":"15469912","source_url":"https://pubmed.ncbi.nlm.nih.gov/15469912/","study_design":null,"title":"The Caenorhabditis elegans IMPAS gene, imp-2, is essential for development and is functionally distinct from related presenilins","title_match":false,"year":2004},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/comparative-effectiveness-of-glucagon-like-peptide-1-agonists-39429814","doi":"10.1016/j.eclinm.2024.102689","journal":"EClinicalMedicine","n_participants":12351,"pmid":"39429814","source_url":"https://pubmed.ncbi.nlm.nih.gov/39429814/","study_design":null,"title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/liraglutide-reduces-vascular-damage-neuronal-loss-and-cognitive-34975451","doi":"10.3389/fnagi.2021.741923","journal":"Frontiers in Aging Neuroscience","n_participants":null,"pmid":"34975451","source_url":"https://pubmed.ncbi.nlm.nih.gov/34975451/","study_design":null,"title":"Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer\u2019s Disease and Type 2 Diabetes","title_match":true,"year":2021},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/therapeutic-potential-of-the-original-incretin-hormone-glucose-20698813","doi":"10.1517/13543784.2010.513381","journal":"Expert Opinion on Investigational Drugs","n_participants":null,"pmid":"20698813","source_url":"https://pubmed.ncbi.nlm.nih.gov/20698813/","study_design":null,"title":"Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?","title_match":false,"year":2010},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/glucagon-like-peptide-1-decreases-intracerebral-glucose-content-by-22929437","doi":"10.1038/jcbfm.2012.118","journal":"Journal of Cerebral Blood Flow & Metabolism","n_participants":null,"pmid":"22929437","source_url":"https://pubmed.ncbi.nlm.nih.gov/22929437/","study_design":null,"title":"Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia","title_match":true,"year":2012},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/risk-factors-in-coronary-heart-disease-14233810","doi":"10.7326/0003-4819-61-5-888","journal":"Annals of Internal Medicine","n_participants":null,"pmid":"14233810","source_url":"https://pubmed.ncbi.nlm.nih.gov/14233810/","study_design":"cross-sectional","title":"Risk Factors in Coronary Heart Disease","title_match":false,"year":1964}]}